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1. INTRODUCTION 
About three thousand of patients had organ transplantation during 
the 2011 in Italy, with more than one thousand of cases, liver is the second 
transplanted organ, mostly due to cirrhosis as a consequence of hepatitis 
[Ministero della salute, report 2011].  
The hepatitis is an inflammatory disorder of the liver that may be 
caused by viruses, drugs, toxins, autoimmune illnesses and metabolic 
disorders of copper or iron (Wilson's disease and hemochromatosis) (figure 
1). Symptoms include jaundice and fever-like symptoms. In particular, five 
unrelated hepatotropic viruses (hepatitis A to E) are the primary causes of 
viral hepatitis. Hepatitis A and E are typically caused by ingestion of 
contaminated food or water. Hepatitis B, C and D usually occur as a result 
of parenteral contact with infected body fluids. Common modes of 
transmission for these viruses include receipt of contaminated blood or 
blood products, invasive medical procedures using contaminated equipment 
and for hepatitis B transmission from mother to baby at birth, from family 
member to child, and also by sexual contact. Among the hepatitis viruses, 
only hepatitis B virus (HBV) and hepatitis C virus (HCV) are capable of 
establishing chronic infections, while hepatitis D virus (HDV) is considered 
a subviral satellite (virusoid) that can establish chronic infection only in the 
presence of an ongoing HBV infection. The World Health Organisation 
(WHO) has estimated that there are more than 500 million people 
worldwide living with chronic HBV and/or HCV infections [Te HS et al., 
2010], all with an increased risk of developing progressive destruction and 
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regeneration of the liver parenchyma leading to fibrosis, cirrhosis and 
possibly hepatocellular carcinoma (HCC). 
Recognizing the tremendous burden caused by viral hepatitis, the 
WHO established the Global Hepatitis Programme in the attempt to reduce: 
i) the transmission of agents that cause viral hepatitis; ii) the morbidity and 
mortality due to viral hepatitis through improving the care of patients with 
viral hepatitis; iii) the socio-economic impact of viral hepatitis at individual, 
community and population levels. 
 
 
 
 
 
 
 
 
Vaccines and antiviral treatment play a topic role in the Global 
Hepatitis Programme, particularly in the case of Hepatitis A Virus (HAV), 
Figure 1. Frequency of liver transplants by diagnosis. With a total of 32% 
viral hepatitis, represented by HBV and HCV, are the most present (yellow 
colored). Alcoholic Cirrhosis (ETOH) is the second cause for liver transplant 
followed by the group of cholestatic diseases, Primary Biliary Cirrhosis 
(PBC) and Primary Sclerosing Cholangitis (PSC), green portion. 
Hepatocellular Carcinomas (HCC) are also present (orange colored, 2%). 
Figureure adapted from Manzarbeitia C et al., 2012 (source 
http://emedicine.medscape.com).  
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HBV and HCV prevention / infection. To date several vaccines against 
hepatitis A are available and highly efficacious providing long-lasting 
protection in adults and in children above one to two years of age. In 
countries where clinical hepatitis A is an important health problem, 
immunization is likely to be a cost-effective public health tool to control the 
disease. No drugs against HAV are currently available, and antiviral 
medication is unlikely to become a realistic alternative to appropriate 
vaccines. Immune globulin may be used for pre- and post-exposure 
prophylaxis, for example, shortly before entering a disease-endemic area or 
just after likely HAV exposure. However, passive immunization with 
immune globulin gives only short-term protection (three to five months) and 
is relatively costly compared to the long-term immunity from vaccination. 
Hepatitis B vaccine is 95% effective in preventing HBV infection and its 
chronic consequences, and is the first vaccine against a major human cancer. 
The vaccine has an outstanding record of safety and effectiveness. Since 
1982, over one billion doses of hepatitis B vaccine have been used 
worldwide. In many countries where 8% to 15% of children used to become 
chronically infected with HBV, vaccination has reduced the rate of chronic 
infection to less than 1% among immunized children. In 2010, 179 countries 
reported that they had included the hepatitis B vaccine into their national 
infant immunization programmes (two of these countries reported 
introducing in part of the country only). This is a major increase compared 
with 31 countries in 1992, the year that the World Health Assembly passed 
a resolution to recommend global vaccination against hepatitis B. 
Furthermore, during the last 15 years, several drugs has been introduced for 
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the treatment of HBV: immune-modulatory agents like interferon α, and 
nucleos(t)ide analogues (NAs) direct acting on the virus replication 
mechanism. The latter, in particular, can avoid the viral replication reducing 
the liver damage due to the inflammation but unfortunately is not able to 
eradicate the Hepatitis B virus from infected hepatocytes determining a 
lifelong treatment for patients affected by chronic hepatitis B (CHB) to 
prevent the recurrence of the virus. Despite advances in treatment, the 
chronic HBV infection can still make progress in the disease in case of 
selection and emergence of drug-resistant viral variants, 
immunosuppression or poor adherence to therapy. For this reason, liver 
transplant (LT) may be the only hope for many CHB infected patients, 
particularly for those with end-stage liver disease. 
Because of the impossibility to completely clear HBV from infected 
cells, a main issue after liver transplant is the HBV graft reinfection, 
probably due to enhanced virus replication resulting from 
immunosuppression and direct stimulatory effects of steroid therapy on the 
glucocorticoid-responsive enhancer region of the HBV genome [McMillan 
JS et al., 1995; Tur-Kaspa R et al., 1988]. Results of LT for HBV have 
improved significantly during the past two decades
 
[Kim WR et al., 2004]. 
In the 1980s, HBV recurrence was highly prevalent post LT, leading to poor 
patient and graft survival
 
[Starzl TE et al., 1984]. Mechanisms of HBV 
recurrence in the graft included: i) immediate reinfection of the graft due to 
the circulating HBV particles, or ii) reinfection of the graft due to HBV 
particles coming from the extra-hepatic sites. Large, single-center data in 
the early 1990s demonstrated increased mortality and graft dysfunction in 
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hepatitis B surface antigen (HBsAg)-positive patients as compared to the 
HBsAg-negative patients undergoing LT [Todo S et al., 1991]. It was seen 
that HBV recurrence in the graft was of a very severe nature, including an 
aggressive variant of HBV-associated liver injury known as fibrosing 
cholestatic hepatitis (FCH) [Davies SE et al., 1991]. However, with the 
introduction of hepatitis B immunoglobulin (HBIg) in the peri transplant 
period, there was a significant reduction in the rate of HBV recurrence post 
LT, with improved patient and graft survival rates, and HBV-induced 
fulminant or end-stage hepatic failure became an accepted indication for LT. 
Refinements made in the antiviral prophylaxis and treatment of HBV 
infection, in particular, the recent introduction of nucleoside analogs, alone 
or in combination, for the treatment of established graft infection have 
remarkably improved the outcome of LT for HBV with the result that few if 
any grafts should succumb to HBV-inflicted damage. 
To date there are no effective vaccines to prevent HCV infection and 
therapy has been limited to a combination of ribavirin and interferon α or 
pegasys interferon α (standard of care, SOC) until 2011, when a new class 
of drugs started to be available for the treatment of chronic hepatitis C: the 
Direct Acting Anti-viral (DAA). The latter has been developed to be used, 
in a triple combination therapy (SOC + DAA), firstly in patients with low or 
no response to the SOC and promising results has been obtained from the 
first clinical trials. Unfortunately the DAA can select HCV variants 
inducing resistance and the risk of progression in liver disease is high like in 
HBV during NAs therapy if not greater. Therefore, management of chronic 
HCV treatments will be one of the main challenge for hepatologist clinician 
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in the next years, particularly considering that end-stage liver disease due to 
chronic HCV infection is the leading indication for LT with a frequency of 
28% of the all diagnosed causes (Figure 1). Moreover, from the data 
available to date, infection is expected to recur, after the LT, in almost all 
patients with active HCV infection before transplant and approximately 20–
30% of these HCV-reinfected patients will develop cirrhosis within 5 years. 
Unfortunately, many transplant recipients who develop cirrhosis are not 
candidates for retransplantation, and outcomes in patients who do undergo 
retransplantation are usually not good. The most reliable way to prevent 
post-transplantation HCV infection is to cure the infection before 
transplantation. However, this approach is not feasible in patients who 
present with decompensated cirrhosis, as use of interferon is contraindicated 
in these patients. Moreover, the achieving of undetectable levels of HCV 
RNA while on treatment may not be sufficient to prevent recurrence of 
HCV infection post-transplantation. A new way to prevent the graft from 
becoming reinfected post-transplantation is to use monoclonal antibodies 
targeting the HCV proteins that help the virus gain entry into hepatocytes. A 
phase II study of these antibodies showed some promise, but an effective 
regimen will require a DAA drug in addition to the antibody
 
[Gonzalez SA. 
2011]. 
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2. HEPATITIS B VIRUS 
 
2.1 HBV biology 
Human Hepatitis B virus (HBV) is classified as a member of the 
Hepadnaviridae family [Gust et al, 1986] (hepatotropic DNA viruses), that 
can be divided into two genera: the Orthohepadnaviruses, infecting only 
mammals, and the Avihepadnaviruses infecting birds. To date, two major 
species have been assigned to the Avihepadnaviruses, the duck hepatitis B 
virus (DHBV) and the heron hepatitis B virus (HHBV). The 
Orthohepadnavirus genus includes the four best-known distinct species 
human hepatitis B virus (HBV), woodchuck hepatitis virus (WHV), ground 
squirrel hepatitis virus (GSHV) and woolly monkey hepatitis B virus 
(WMHV). The host range of Orthohepadnavirus varies in the different 
species allowing in some case the possibility to have more infecting animal 
models. WHV, is a well studied orthohepadnavirus that occurs naturally in 
marmots and cannot be transferred to other rodents like its relative GSHV 
[Summers et al., 1978; Mason et al., 1980]. GSHV can infect woodchucks, 
thus its host range is not as narrow as the WHV host range. Finally, the 
WMHV, despite having a non-human primate as its natural host, in contrast 
to HBV, is not infectious for chimpanzees [Lanford et al. 1998]. 
 
2.1.1 Morphology of HBV 
The infectious HBV virion (Dane particle) is spherical shaped and 
has a  diameter of 42-47 nm. External envelope consists of a cell derived  
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phospholipidic bilayer with three different surface protein embedded in it. 
These proteins, according to their size are named HB small surface antigen 
(SHBsAg), middle (MHBsAg), or large (LHBsAg). The nucleocapsid, 
which forms the inner part of the Dane particle, is around 28 nm in size and 
contains a single copy of the circular partially double-strand genomic DNA 
which is covalently linked to the viral reverse-transcriptase (figure 2).   
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  HBV structure  
 
The average size of the viral genome is around 3.2 kbp, varying 
slightly from genotype to genotype and from isolate to isolate. The viral 
genome encodes for the core protein (HBcAg), the pre-core protein also 
known as the e-antigen (HBeAg), the polymerase, the three surface proteins, 
and the X protein. 
 
 
42-45 nm
Polymerase (P)
DNA
Medium Surface protein
Large Surface protein
Small Surface proteinIcosahedral core (C)
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2.1.2 HBV Genome and Proteome 
The HBV genome is a relaxed circular, partially double stranded 
DNA of approximately 3,200 base pairs. There are four partially 
overlapping open reading frames encoding the envelope (Pre-S/S), core 
(Precore/Core), Polymerase, and X proteins (figure 3) [Tiollais et al. 1985; 
Seeger et al. 2000]. All open reading frames are in an identical orientation 
and overlap at least partially. Within the Dane particle the negative strand of 
the viral genome is present in full-length, thus carrying the whole genome. 
In contrast, the positive strand spans only ~ 2/3 of the genome in length, 
being its 3’-end is variable in size [Lutwick et al. 1977; Summers et al. 
1975). The viral polymerase is covalently bound to the negative strand by a 
phosphotyrosine bond. At the 5’-end of the positive strand a short RNA 
oligomer originating from the pre-genomic (pg) RNA remains residually 
bound covalently after the viral DNA synthesis. The negative strand, in 
contrast to the positive strand, contains on both the 5’-end and the 3’- end a 
small redundancy of 8-9 nucleotides in length, named the R-region. These 
redundant structures are essential for viral replication [Seeger et al. 1986; 
Will et al 1987; Lien et al. 1986]. The viral genome covers four open 
reading frames, all of them encoded by the negative strand, with 6 start 
codons, four promoters, two transcription enhancing elements, a poly-
adenylation signal motif, and a number of signals for DNA replication. 
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Figure 3. HBV genome organisation 
 
The major RNA transcripts are polyadenylated, capped and named 
pre-C/C, preS, and S mRNAs [Enders et al., 1985; Cattaneo et al., 1984]. 
Moreover, a 0.7 kb long mRNA termed X mRNA occurs occasionally. The 
3’-end of all HBV transcripts is common for all of them and created by the 
polyadenylation signal in the core (C) gene. 
 
 
 
 
 
ε
PreC/C(pregenomic mRNA
X
PreS
2/S
P
re
S
1
P
oli A
A
A
DR1
DR2
X
C
preC
Pre
 S1 Pre S2
S
P
HBV
3,2kb
2114
948
549
29023
18
2
3096
3117
2658
407
19 
 
2.1.3.a  S gene/HBsAg  
The S gene encodes for the three distinct but related surface proteins 
termed S, M and L by a single open reading frame referred as ORF-E. This 
ORF is 389 or 400 codons in length depending on viral subtype and  
consists of three 5′ in-phase ATG codons for the initiation of translation and 
one 3′ TAA termination codon. Thus, the three HBV surface proteins only 
differ by the length of their N-terminal domains and are essential for 
envelopment of nucleocapsids. All three envelope components are 
glycosylated, type II transmembrane proteins, that can form multimers 
stabilized by disulfide bridges formed by cysteine residues present in the S 
domain. The L protein is characterized by the addition of a 108 to 119 
residue sequence named “PreS1” on the N-terminus of M. Thus, this large 
protein basically incorporates the preS domain (preS1 and preS2) to the N-
terminus of S [Heermann et al. 1984]. Currently, it is clearly recognized that 
L plays a specific role in the viral cycle: recruitment of a mature viral 
nucleocapsid for virion budding [Bruss, 2007] and recognition of the 
cellular (co-)receptor(s) for virus entry [Glebe and Urban, 2007], 
respectively. The 226 aa S protein traverses the membrane at least twice 
with transmembrane region 1 (TM1) and TM2 and is produced at the rough 
endoplasmic reticulum (ER) [Bruss, 2007]. The biosynthesis of the 281 aa 
M protein is quite similar to S and has a similar topology. This protein 
differs from S by the N-terminal addition of a 55 residue sequence named 
“PreS2”. However, the exact role of M protein in the viral cycle remains 
unclear. Indeed, its in vivo absence in infected cells does not disrupt viral 
morphogenesis or particle functionality [Fernholz et al., 1991]. Thereby, 
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this protein seems not to be essential for virus spread and its complete 
absence from the Avihepadnavirus genomes reinforces this hypothesis.  
The S, L, and M proteins are all found as components of the Dane 
particles. However, the surface proteins are not only incorporated into virion 
envelopes but also form subviral spherical particles without nucleocapsids. 
These particles assemble at a pre-Golgi membrane [Huovila et al., 1992] 
together with lipid, have a diameter of 20 nm, and are spherical or 
filamentous in shape (figure 4). The Large surface protein is an essential 
component of both virions and filaments and represents 10% of their 
envelope proteins. In contrast, it represents only 1% of the 20 nm spherical 
particles. The M protein is present in equal amounts in Dane particles and 
filaments and constitutes 10% of the 20 nm spherical particles.  The S 
protein by itself is an essential component of virions, filaments and spheres 
(70-89%). Subviral HBsAg particles exceed virions by a variable factor of 
10
2–105 and can accumulate up to concentrations of several hundred 
micrograms per milliliter of serum in the blood of HBV-infected patients 
[Seeger et al., 2000]. 
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Figure 4. Morphology of HBV particles, HBs filaments and HBs spheres -  
[adapted from: Molecular Biology of Hepatitis B virus- Heermann KH and 
Gerlich WH-  CRC press (1991)] 
 
In addition to the serum, HBsAg can be detected in the infected 
hepatocytes with different expression patterns according to the different 
phases of infection. It has been shown that there is membranous staining of 
HBsAg associated with variable degrees of cytoplasmic staining of HBsAg 
during the phase of active hepatitis B virus replication and, by the contrast, 
solely cytoplasmic staining of HBsAg during the non-replicative phase 
[Gudat et al., 1975; Ray et al., 1976; Montano et al., 1982]. Membranous 
staining of HBsAg on the hepatocyte correlated excellently with serum 
HBV DNA and could be recognized as a marker of active hepatitis B virus 
replication [Chu et al., 1995]. 
 
 
 
 HBV particles                     HBsFilaments                      HBsSpheres
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2.1.3.b PreC/C gene/ HBeAg, HBcAg 
The PreC/C ORF contains two in-frame translation initiation signals 
separated by 28 codons, thus encoding both precore protein,  precursor for 
the viral e antigen (HBeAg), and Hepatitis B virus core antigen (HBcAg) 
[Uy et al., 1985; Seeger et al., 1986]. Synthesis of precore protein is 
initiated from the first ATG and core protein from the second at positions 
1814 and 1901 respectively. The precore protein therefore initially contains 
all of the core protein sequence plus 29 amino acids at its N-terminus. These 
constitute a signal peptide that directs the nascent chain to the endoplasmic 
reticulum and the secretion pathway.  
The first 19 amino acids are cleaved off and during transport to the 
cell surface the protein is further matured by removal of the highly basic C-
terminal tail. Production and secretion are modulated at both transcriptional 
[Okamoto et al., 1994; Laskus et al., 1994] and translational [Brunetto et al, 
1989; Carman et al., 1989; Okamoto et al., 1990] levels and the protein is 
released as a soluble antigen, HBeAg [Standring et al., 1988]. HBeAg is not 
a structural component of the virion, it is not required for viral replication, 
however its secretion is conserved in both Orthohepadnaviruses and 
Avihepadnaviruses and its synthesis is tightly regulate at transcriptional and 
translational levels. This it is supposed to be due to an immune-regulatory 
function promoting virus persistence by inducing neonatal tolerance and 
modulating the immune-response in adults  [Chang et al., 1987; Chen et al., 
1992, Milich et al., 1997]. The core protein which itself can be 
phosphorylated by several kinases, is essential for the formation of 
nucleocapsids. It plays an active role in binding and packaging of the 
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pregenomic RNA, recruitment of the viral polymerase, and thus enables the 
RT-polymerase/RNA complex to initiate reverse transcription within the 
newly forming nucleocapsids [Lan et al., 1999; Gerlich et al., 1982 1982; 
Watts et al.,  2002]. Although HBcAg and HBeAg show substantial amino 
acid sequence homology, they are serologically distinct, and the immune 
responses to these antigens appear to be regulated independently. HBcAg is 
highly immunogenic (0,025 mg of HBcAg elicit antibodies production) and 
functions as both T-cell independent and T-cell dependent antigen. 
Immunization with HBcAg preferentially primes Th1 cells; and HBcAg-
specific Th cells mediate anti-envelope as well as anti-HBc antibodies 
production. 
The HBcAg is a major target of CTL response. High levels of 
soluble anti-HBc, as observed in most of HBV infected individuals, may 
compete with B cells Ig receptor mediated  uptake of HBcAg with inhibition 
of TH cell activation. The immune response to HBeAg is strictly T cell-
dependent [ Milich et al., 1986] and HBeAg preferentially, but not 
exclusively, elicits Th0 or Th2-like cells which stimulate the humoral 
immune reaction [Milich et al., 1997].  In particular, HBeAg-specific Th2 
cells may cross-regulate HBcAg-specific Th1 cells or the secreted HBeAg 
may preferentially behave as a tolerogen and inactivate HBcAg-specific T 
cells through deletion or clonal anergy in the periphery [Chen et al., 2005; 
Milich, 1997; Milich et al., 1998]. T-cell anergy is a tolerance mechanism in 
which the T cell is functionally inactivated following an initial antigen 
encounter but remains alive in a hypoactivated state. 
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2.1.3.c P gene/Polymerase 
The P ORF, covering nearly 80% of the hepadnaviral genome (1685 
nt), encodes a multifunctional protein including the terminal protein (TP) 
that acts as a primer for HBV DNA synthesis and the viral polymerase that 
possesses DNA polymerase, reverse transcriptase (RT) and RNaseH 
activities. During replication, a pre-genomic RNA is produced that encodes 
for both HBcAg and polymerase [Nassal et al. 1996; Nassal 1999]. 
Polymerase is the second ORF on this messenger RNA (mRNA) and 
partially overlaps with the 3’ end of the HBcAg cistron. The HBV 
polymerase is not proteolytically cleaved to mature enzymatically active 
proteins, but consists of 4 domains [Lanford et al. 1999]: a TP domain, 
which becomes covalently linked to negative-strand DNA during initiation 
of reverse transcription [Weber e al. 1994; Zoulim et al. 1994] a spacer 
domain, which is very tolerant to mutations and can be partially deleted 
without affecting polymerase activity [Li et al. 1991; Radziwill et al. 1990; 
Kim et al. 1999]; the reverse transcriptase/polymerase (RT domain), which 
contains the conserved regions A through F, characteristic of RNA-
dependent RNA polymerase (RdRP) and RNA-dependent DNA polymerase 
(RdDP) [Poch et al. 1989; Lesburg et al. 1999]; and the ribonuclease H 
domain (RH domain)[Wei et al. 1996].  
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2.1.3.d X gene/X protein 
The X ORF is located downstream to enhancer 1 (Enh I) and is 
partly overlapped by the P  ORF at its N terminus and by the PreC/C  ORF 
at its C terminus [Tiollais et al. 1985]. Furthermore, the X ORF is 
overlapped by several cis-elements including enhancer II (Enh II) [Yee, 
1989], several cis-elements for transcriptional regulation, and the PreC-C 
promoter. The X gene is transcribed independently of the other viral 
transcripts  and a separate X mRNA of 0.8 kb has been detected in liver 
tissues of both human and woodchuck [Kaneko et al.,1988; Guo et al., 
1991] as well as in transgenic mice [Kim et al., 1991]. So far, the role of the 
X protein is not fully understood, indeed, although HBx does not bind DNA, 
the first activity identified for this viral protein was the ability to activate 
transcription of viral and cellular genes [Twu et al., 1987]. HBx is a weak 
transactivator, but it is capable to activate a variety of cellular and viral 
promoters. This broad spectrum of activities relies on two different 
mechanisms: either direct interaction with nuclear transcriptional regulators, 
or activation of signal transduction pathways [Wei et al., 2010]. HBx has 
also been implicated in pleiotropic activities such as cell cycle regulation, 
activation of signaling pathways, modulation of apoptotic pathways, and 
inhibition of DNA repair [Andrisani et al. 1999; Bouchard et al., 2004; 
Tang et al. 2006]. 
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2.1.4 HBV life cycle 
Hepatocytes are the primary site of viral DNA replication. It is 
assumed that viral entry and the host range of hepadnavirus is dependent on 
the N-terminus of the large surface antigen [Ishikawa et al., 1995; Chouteau 
et al., 2001; Lambert et al., 1990; Gripon et al., 2005; Urban et al., 2002]. 
So far, the intrinsic HBV receptor has not been discovered, but from studies 
on DHBV in primary duck hepatocytes it is assumed that around 104 
receptor molecules per cell mediate the rapid binding, followed by a slow 
uptake of the virus to the cell which can take up to 16 hours [Pugh et 
al.,1989; Klingmuller et al.,1993; Pugh et al., 1995]. Following entry the 
nucleocapsid is transported into the cell nucleus, where the viral nucleic 
acid is released. Release of the viral DNA and disintegration of the 
nucleocapsid is assumed to take place at the nuclear core complex [Kann et 
al., 1997; Rabe et al., 2003] (figure 5). 
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The life cycle of hepadnaviruses is characterized by the synthesis of 
a 3kb partially double-stranded, relaxed-circular DNA (rcDNA) genome by 
reverse transcription of an RNA intermediate, the pregenome. The 
mechanism of RNA-directed DNA synthesis has been well characterized 
[Ganem et al., 1994; Seeger et al., 1996]. After virus penetration the DNA 
reaches the nucleus and is immediately converted by host enzymes to 
complete open circular double-stranded DNA and then to supercoiled DNA 
(cccDNA) (figure 5). Since cccDNA, which accumulates only in the 
nucleus, is the template for the transcription of all viral mRNAs, its 
formation indicates a successful initiation of infection. The viral RNAs 
include pregenomic RNA (pgRNA), which serves as the template for 
reverse transcription, as well as three subgenomic mRNAs necessary for the 
translation of the envelope proteins and the mRNA for the X protein. The 
pgRNA is both the template for core and polymerase protein translation and 
is the matrix for the progeny genomes. The pgRNA bears a secondary 
structure - named ε-structure - that is present at both the 5’- and the 3’-ends. 
The ε-hairpin loops at the 5’-end are first recognized by the viral 
polymerase and act as the initial packaging signal [Bartenschlager et al., 
1992; Hirsch et al., 1990; Huang et al., 1991] (figures 5). In the cytoplasm, 
the core protein forms the basis for the nucleocapsid. It plays an active role 
in binding and packaging of the pregenomic RNA, recruitment of the viral 
polymerase, and thus enables the RT-polymerase/RNA complex to initiate 
reverse transcription within the newly forming nucleocapsids.  Finally, in 
the endoplasmic reticulum, the nucleocapsid acquires the external coat. In 
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the early stages of infection the nucleocapsid is also transported to the 
nucleus in the hepatocyte to increase cccDNA copies [Nassal et al., 1993; 
Nassal et al., 2000] (figure 5). 
The HBV DNA is able to integrate into the host genome. The 
integration occurs in different sites and usually affects only one part of the 
viral genome, which retains the ability to be transcribed. The integration of 
HBV DNA is an early event in the natural history of infection and is 
implicated in the pathogenesis of hepatocellular carcinoma: the integration 
within or near cellular genes involved in regulating cell cycle, could result 
in an alteration of their function promoting in the hepatocytes affected a 
neoplastic transformation. 
 
 
2.1.5 Viral Heterogeneity 
Changes in the viral genomes occur randomly as errors in the 
replication. These can be nucleotide substitutions (point mutations), deletion 
or insertions. Usually DNA viruses have a more stable genome than those 
RNA, because of the proofreading capacity of the host enzyme that they 
exploit for replication. The Hepadnaviridae genome represent an exception. 
Although their genome is a double-strand DNA, these viruses replicate 
through a RNA template which is reverse transcribed by a enzymatic 
complex that lacks the proofreading capacity. On the other hand, the HBV 
genome in particular, has a  very compact organization and even a single 
nucleotide substitution may result in pleiotropic effect. For this reason, the 
number of mutations that can be tolerated without losing infectivity and 
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replication capacity is rather limited [Miller et al., 1989]. Indeed, any 
mutant selection is related to its biological efficiency and ability to escape 
immune pressure, both humoral and cellular, and/or selective pressure 
exerted by antiviral drugs that directly interfere with viral enzymes. 
Moreover, in chronic hepadnavirus infections, net virus expansion cannot 
occur indefinitely. The maximum amount of virus, or viral cccDNA, in the 
liver is limited by the number of hepatocytes that can be infected and the 
maximum number of cccDNA copies per hepatocyte. In a fully infected 
liver, new cccDNA synthesis is prevented unless uninfected cells are 
generated by liver growth or cell turnover or unless existing cccDNA 
molecules are lost and replaced within the cell. Turnover of cells or 
cccDNA thus provides an opportunity for enrichment of one virus strain 
over another through competitive growth [Zhang et al., 2000]. This explains 
why, despite the relatively high mutation rate of HBV (approximately 2 x 
10
4
 nucleotide substitutions/site/year), only a small proportion of mutants 
can survive [Girones et al., 1989]. 
 
 
2.1.5.a S gene mutations 
The envelope proteins of HBV are targets of both humoral and 
cellular immune response that are involved in viral clearance. Anti-HBs 
antibodies show neutralizing activity and are essential to limit the spread of 
the infection. As a consequence, envelope proteins have been used in the 
prophylaxis of HBV infection for preparation of the vaccines and 
production of antibodies for therapeutic purposes [Neurath et al., 1986; 
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Vento et al. 1987; Nayersina et al.,1993; Jin et al., 1995]. Some of the 
envelope mutants determine the different subtypes of HBV and may have 
been selected over centuries perhaps under HLA pressure.  
In the recent years, many variants have been identified in the S gene 
and some of these mutations produce changes in the epitopes recognized by 
the current diagnostic assays determining the undetectability or a lower 
sensitivity to the HBsAg quali / quantitative assays [Carman et al., 1995; 
Carman et al., 1997; Mühlbacher A et al., 2007]. Most frequently, point 
mutations occur in the area of the “a” determinant (124-147 aa), and also the 
immune response induced by recombinant vaccines that are current 
available seems to focus on this region as target. The first “vaccine escape 
mutant” described [Carman et al., 1990] was substitution of a Glycine 
residue at position 145 by an Arginine residue (G145R), which has been 
identified also in chronic carriers [Carman et al., 1990]. Many other 
substitutions in the “a” determinant (I/T126A/N, A128V, Q129H/R, 
G130N, M133L/T, K141E, D144A/H) have since been associated with 
immune escape [Cooreman et al., 2001], but G145R is by far the most 
common variant. Immune escape mutants with substitutions outside of the 
“a” determinant have also been described [Oon et al., 1999], the most 
important of which is P120S/T and the loss of cysteine 124 abolishing 
HBsAg secretion in a HBsAg negative/HBV DNA positive patient. The 
other medical condition associated with the emergence of envelope variants 
is treatment with monoclonal antibodies or hyperimmune human 
immunoglobulin (HBIg) which is used to prevent HBV recurrence in 
patients transplanted for HBsAg-positive cirrhosis. Similar to vaccine 
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recipients, a glycine/arginine substitution at position 145 and aspartic 
acid/alanine at aa 144, are the most common variants found in these cases 
[Carman et a., 1996]. Another mutant described in a HBsAg negative/HBV 
DNA positive patient was the loss of cysteine 124, abolishing HBsAg 
secretion.  
Many mutations affect the PreS domains of the envelope proteins, 
most of which are deletions [Kay et al., 2007]. PreS mutants emerge in 
chronic infections, often in patients treated with interferon [Gerner et al., 
1998; Santantonio et al., 1992], and probably represent attempts by the virus 
to evade host immune responses. The emergence of pre-S mutants could 
play a role in viral persistence; however, their implication in the 
pathogenesis of liver damage cannot be excluded [Brunetto et al. 1999]. The 
region of the S gene coding the PreS1 and PreS2 domains is overlapped by 
the region of the P gene coding the spacer domain of the viral polymerase. 
This domain gives flexibility to the viral polymerase, but its sequence is not 
absolute and can suffer in-phase deletions and insertions without affecting 
the enzymatic activities of the protein. However, there are constraints on 
PreS1 mutations due to the fact that its N-terminus (residues 21–47 of the 
genotype D PreS1) is important in viral attachment to hepatocytes [Neurath 
et al., 1986] and the S promoter is located in the 3’ extremity of the PreS1 
coding region. In addition, some mutations can result in intracellular 
retention of the PreS1 protein [Bock et al., 1997; Melegari et al., 1994] 
which inhibits virion secretion and is cytotoxic. As a result, although PreS1 
deletion mutants are replication competent, they usually need a helper virus 
and are found as minor viral populations. On the other hand, there appear to 
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be few constraints on PreS2 mutations since its product is not essential for 
viral replication, particle morphogenesis and secretion and infectivity 
[Fernholz et al., 1991]. Mutations include deletion or missense mutation of 
the PreS2 ATG, thereby abrogating synthesis of the protein, and deletions or 
alterations of B- and T-cell epitopes. HLA class I-restricted, cytotoxic T 
cells recognize short viral peptides that are generated by the intracellular 
processing of endogenously synthesized viral antigens within infected cells, 
and are expressed at the cell surface in the binding groove of selected HLA 
class I molecules. Single amino acid substitutions of MHC anchor residues 
or TCR contact sites have been shown to abrogate CTL responses in vitro 
by inhibiting either HLA binding or TCR recognition of the peptide. The 
most common mutation affecting the PreS2 region involves the first part in 
which is MHC class I-restricted T-cell epitope [Bertoletti et al, 1994; 
Chisari et al., 1995; Sobotta et al., 2000; Fan et al., 2001;]. An association 
between pre-S2 mutant (start codon mutants preventing pre-S2 protein 
synthesis) infection  and fulminant hepatitis has been described, and a direct 
role of these variants in the induction (via an abnormal immune response or 
a direct cytopatic effect) of severe liver damage has been hypothesized 
[Pollicino et al., 1997]. Mutations in the S gene may lead to different 
histological liver features. Glassy or ground glass hepatocytes (GGH) 
ultrastructurally are characterized by an abundance of smooth endoplasmic 
reticulum (ER), among which HBsAg is accumulated and are different in 
morphology and distribution at different replicative stages of chronic HBV 
infection [Hadziyannis et al., 1973]. Recently, intracellular study have 
revealed that ground glass hepatocyte may contain specific mutants and 
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exhibit differential biological activities [Wang et al., 2003; Su et a., 2008].  
Type I GGHs expressed an inclusion-like pattern of hepatitis B surface 
antigens and harbored mutants with deletions over pre-S1 region, whereas 
type II GGHs, distributed in clusters and emerged at late replicative phase, 
contained mutants with deletions over pre-S2 region that defines a cytotoxic 
T lymphocyte (CTL) immune epitope, and may represent an immune escape 
mutant. 
 
 
2.1.5.b PreC/C region mutations: HBeAg defective Mutants 
During chronic HBV infection, two major types of HBV core gene 
variants frequently occur that affect the expression of HBeAg: the PreCore 
(PreC) mutants and the basic core promoter (BCP) mutants.  
As described above, the secretion of the antigen "e" depends on the 
expression of a specific leader peptide which is encoded by  HBV PreC 
region. In 1989 two independent studies performed in anti-HBe positive 
patients of the Mediterranean area showed that the most frequent cause of 
the discrepancy between the presence of HBV DNA and the absence of 
HBeAg was the infection with HBV variants unable to secrete the soluble 
form of the HBV nucleocapsidic protein (HBeAg minus mutant) [Brunetto 
et al, 1989; Carman et al., 1989]. The HBeAg production and secretion are 
modulated both at the transcriptional [Okamoto et al. 1994; Laskus et al., 
1994, Jaw et al., 1991] and translational levels [Brunetto et al., 1989, A; 
Carman et al., 1989, Okamoto et al., 1990, Raimondo et al., 1990; Brunetto 
et al., 1999]. The most prevalent PreC mutation that affect the HBeAg 
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expression at the translational level, is a guanine to adenine transition at 
nucleotide position 1896 (G1896A), which creates a TAG stop codon at 
codon 28 of the PreC protein [Brunetto et al., 1989; Carman et al, 1989; 
Raimondo et al., 1990; Ganem et al., 2001] (figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 6  Nucleotide composition of epsilon signal. 
 
However, this mutation is located within the epsilon (ε) structure, a 
highly conserved stem-loop essential for initiation of encapsidation within 
the viral replication cycle. In order to stabilize this ε structure, the 
nucleotide at position 1896 is paired with the nucleotide at position 1858, 
which naturally is a thymidine in genotypes B, C, D, E, and G and a cytidine 
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in genotype A. Therefore, in HBV genotype A, the G1896A mutation 
usually arises together with a C1858T nucleotide exchange [Lok et al., 
1994; Rodriguez-Frias et al., 1995]. These HBV mutant, termed HBeAg 
minus or defective is predominant, in the mediterranean area, in 90% of 
HBV chronic carriers anti-HBe positive [Brunetto et al, 1989; Raimondo et 
al., 1990; Kojima et al., 1991; Santantonio et al., 1992; Tong et al, 1992]. 
As previously shown, wild-type and HBeAg minus HBV may coexist in a 
HBV carrier and their relative ratio vary over time [Brunetto et al., 1991; 
Brunetto et al., 1993; Brunetto et al., 1994; Brunetto et al., 1994b; Brunetto 
et al., 1997]. Furthermore, as discussed later, follow-up studies suggested 
the important association between different ratios of circulating wild type 
and HBeAg minus HBV and pathogenetic events during the course of 
chronic hepatitis B [Brunetto et al., 1994; Brunetto et al., 1997]. In vitro 
experiment showed that the precore region and pgRNA transcription are 
under control of regulatory elements such as the Basic Core Promoter (BCP) 
and the Core Upstream Regulatory Sequence (CURS) [Yuh et al., 1992]. 
Mutations in these domains appear to affect mRNA transcription, notably by 
decreasing the synthesis of HBeAg [Okamoto et al., 1994]. Cytokines,  such 
as tumor necrosis factor alpha (TNF-α) and interferons alpha and gamma 
(IFN-α and γ), held the transcription inhibitory activity by acting directly on 
BCP [Romero et al., 1996].  
Other mutations that act at translational level are a thymine (T) 
instead of a cytosine (C) at nucleotide 1817 and an A instead of a G to 1897, 
both of which give rise to translational stop codons. Two mutations were 
also observed: G T and T C in position 1816 and 1815 respectively, 
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responsible for the elimination of translation start codon of the pre-core 
region. All these mutations leads to the same result: a defective virus of “e” 
antigen [Brunetto et al, 1989; Carman et al., 1989 Santantonio et al., 1992; 
Tong et al, 1992].  
The most common BCP mutation is the double A1762T and 
G1764A nucleotide exchange, which results in a decrease of HBeAg 
expression of up to 70% but enhanced viral genome replication [Buckwold 
et al., 1996; Hunt et al., 2000; Locarnini et al., 2003]. Moreover, 
considering the regulatory activity of these region, carriers infected with 
HBV with the BCP mutations resulting in gene deregulation, may be at 
increased risk for hepatocellular carcinoma [Lee, 1997]. 
 
2.1.5.c P gene mutations 
Mutations in the P gene are not very frequent during the HBV 
natural infection and limited to those that result from the host immune 
pressure on the S gene region overlapping the polymerase/retrotranscriptase.    
Mutations in the P gene especially occur during NAs prolonged treatment 
and are selected because allow the Pol/Rt to recover the replication 
efficiency avoiding and resisting to the chain terminator nucleos(t)ide 
analogue. Because of their strong association with NAs treatment the HBV 
resistant variants will be described later, along with the HBV treatments. 
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2.1.5.d X gene mutations 
Mutations in the X region may involve replication regulatory 
elements such as basic core promoter (BCP) and enhancer II: three AT-rich 
regions are present in BCP, each of them would represent an independent 
binding site for liver-enriched factors for initiating the transcription of the 
different 3.5 mRNAs [Lopez-Cabrera et al., 1990]. The BCP mutations are 
located most frequently in the second AT-rich region (1762 A to T switch 
and 1764 G to A switch); occasionally, point mutations have been described 
in the first AT-rich region, whereas no mutations have been observed in the 
third region, which could induce a decrease in the transcription of genomic 
mRNA [Okamoto et al., 1994;  Sato et al. , 1995]. In fact, it has been shown 
that point mutations in the TATA box of eukaryotic promoters drastically 
decrease in vitro transcription, and mutations in the AT region of viral 
promoters should have similar effects [Corden et al., 1980].  
 
 
2.1.5.e Genotype and Geographical distribution 
Genotypes or genetic subtypes are genetically related strains and 
have been described for viruses belonging to several different families. Four 
genotypes, A–D, of HBV, originally designated as genomic groups, were 
based on > 8% inter genotype and <4% intra genotype divergences, when 18 
complete genomes were compared [Okamoto et al. , 1988]. Later research 
has identified other four HBV genotypes, E–H [Norder et al., 1992; Norder 
et al. 1994; Naumann et al 1993; Stuyver at al. 2000; Arauz-Ruiz et al. 
2002]. Two genotypes, A and F, have been further subdivided into 
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subgenotypes identified by arabic numerals [Kramvis et al., 2002; Kimbi et 
al. 2004, Norder et al. 2003]. The eight genotypes identified to date, are 
distributed in different geographical areas. Genotype A is present in North 
Europe and North America, genotypes B and C are typical of the East Asian 
countries, genotype D is spread all over in the world but mainly in the 
mediterranean area, genotype E is most common in Africa, F and H are 
endemic of South and Central America respectively, finally genotype G was 
firstly isolated in France but is rare and always found in coinfection with 
other genotypes (mainly A). HBV genotypes may influence the course of 
disease and among these relevant biological differences has  been 
recognized. The classical precore mutation, located at HBV nucleotide 1896 
consisting of a G-A substitution that creates a stop codon, is not found in 
genotype A. Genotype A (and F2) contains a cytosine at position 1858 
instead of a uracil, that stabilizes the PreC loop, not allowing the 1896 G-A 
precore mutation to occur [Li et al., 1993].  Indeed, the HBV genotypes B, 
C, D and E are predisposed to develop the mutation at 1896 precore, which 
will result in an earlier seroconversion to anti-HBe. Genotype A 
(presumably A2) infection was associated with a significantly higher 
cumulative rate of sustained biochemical remission, HBV DNA clearance, 
and HBsAg clearance in patients with chronic HBV infection than genotype 
D infection [Sanchez-Tapias et al., 2002]. Multiple studies have shown that 
patients with genotype C experience HBeAg seroconversion at an older age 
and are more likely to be HBeAg positive at any given age than HBV 
genotype B [Chen et al., 2004; Kao et al., 2002; Kao et al., 2004]. HBV 
genotype C is associated with an increase risk of liver inflammation, flares 
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of hepatitis, liver fibrosis, and cirrhosis. Persons infected with genotype D 
usually convert from HBeAg to anti-HBe in adolescence or early adulthood. 
The precore mutant is frequently associated with HBV seroconversion in 
this genotype. While it appears that many persons go into and remain in the 
inactive carrier phase, some persons develop HBeAg-negative/anti-
HBepositive chronic hepatitis B. This can lead to cirrhosis and HCC 
[Naoumov et al., 1992; Grandjacques et al., 2000; Hadziyannis et al., 2001; 
Brunetto et al., 2002; McMahon, 2005; Zacharakis et al.,2005]. Genotype F 
is divided into four subtypes: F1–F4 [Devesa et al., 2008]. Genotype F2 
codes for C at position 1858 and therefore PreC mutation does not occur, 
whereas F1 does not and thus PreC mutation can occur [Schaefer, 2005].  
 
 
2.2 HBV infection and disease  
HBV can cause a transient or chronic liver disease. The transient 
infection may be mild and asymptomatic or cause an acute hepatitis with 
varying degrees of severity to result in 0.5% of patients a fulminant 
hepatitis. The HBV is not directly cytopathic for the infected cell [Guidotti 
et al., 1995; Chisari et al., 2000; Guidotti et al., 2006] and damage is 
induced by the host immune reaction. Correlative clinical studies show that 
in acute, self-limited hepatitis B, strong T-cell responses to many HBV 
antigens are readily demonstrable in the peripheral blood [Chisari et al., 
1995]. These responses involve both major-histocompatibility-complex 
(MHC) class II–restricted, CD4+ helper T cells and MHC class I–restricted, 
CD8+ cytotoxic T lymphocytes. By contrast, in chronic carriers of HBV, 
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such virus-specific T-cell responses are greatly attenuated, at least as 
assayed in cells from the peripheral blood. It has been show that the 
resolution of infection occurs through the coordinated activity of cytokines 
(IFN α and TNF α released by lymphocytes and the cytolitic response that 
leads to infected hepatocytes elimination [Ando et al., 1994; Guidotti et al., 
1994a; Guidotti et al., 1994b; Guidotti et al., 1996; Guidotti et al., 1999a; 
Guidotti et al., 1999b; Guidotti et al., 2000; Kakimi et al., 2001; Tsui et al., 
1995]. The natural history of chronic HBV infection develops over decades, 
the subject is often infected at birth or early in life and keeps for several 
years a state of tolerance or weak activation during which the level of liver 
damage is minimal compared to high replication. Indeed, it is assumed that 
an “immune-tolerant” conditions it is established in those cases in which the 
host immune system is compromised or does not recognize the viral 
antigens (i.e., if the exposition to the virus occurs during the intrauterine 
life) [Milich et al., 1990]. This condition is common in children born from 
HBeAg-positive mothers and infected with HBV in the perinatal period 
[Lee et al., 1990; Bortolotti et al., 1990; Moyes et al., 1993]. In this case, 
the  exposure during pregnancy to circulating HBeAg promotes a tolerance 
state towards viral nucleocapsid antigens (HBcAg and HBeAg), which is the 
main target of cell-mediated response. The immune-tolerant phase can last 
for a few years to more than 30 years [Hui et al., 2007]. During this phase, 
the markers of infection (HBsAg and anti-HBc) and replication (HBeAg and 
HBV DNA), are present in the sera of infected individuals whereas are 
absent those of virus-induced damage (IgM anti-HBc). In the liver there is 
either no or minimal liver inflammation or fibrosis, a high percentage of 
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hepatocytes express hepatitis B core antigen, predominantly in the nuclei, 
while HBsAg show an extensive membranous staining.  
Once the viral antigens are recognized by the immune system, the attempt to 
control the infection through the block of viral replication (cytokine-
mediated) and infected hepatocytes elimination (cell-mediated) begins. 
Liver infiltration by lymphocytes, observed during viral hepatitis, is the 
main pathogenetic moment. These phase, termed “immune-activation”, can 
persist for years with alternating phases of exacerbation and remission. In 
the serum are present markers of viral replication, with typical fluctuations 
in viremia levels, of liver damage and of virus-induced liver damage 
[Brunetto et al., 2001]. In the liver the expression of HBcAg appears to be 
focal in the nuclei or  cytoplasmic whereas HBsAg stains mainly in the 
cytoplasm either in perinuclear blush to a dense signal corresponding to 
ground-glass cells. Most frequently, the immune activation leads to an 
inactive hepatitis B phase, characterized by the absence of HBeAg and the 
presence of anti-HBe, normal ALT levels, low HBV DNA levels (<2000 
IU/ml), and absence or minimal liver fibrosis and inflammation [De 
Franchis et al., 1993; Martinot-Peignoux et al., 2002; Zacharakis et al., 
2005]. However, a significant proportion of patients, after seroconversion, 
retain evidence of viral replication and virus-induced liver damage. This 
condition is typically associated with the prevalence of a viral population 
unable to secrete the HBeAg [Bonino et al., 1981; Bonino et al., 1986; 
Brunetto et al., 1989b; Ulrich et al., 1990; Bonino et al., 1991; Brunetto et 
al., 1991; Bortolotti et al., 1993; Brunetto et al., 1994; Hadzyannis, 1995; 
Brunetto et al., 1997; Brunetto et al., 2001; Brunetto et al., 2002]. This 
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HBeAg defective mutant has been demonstrated during the exacerbation of 
the immune elimination phenomena preceding HBeAg seroconversion to 
anti-HBe, becoming the majority viral population in the HBe negative/anti-
HBe positive chronic hepatitis B, which is prevalent in patients infected 
with genotype D of HBV in the Mediterranean area.  The disease caused by 
HBeAg minus HBV runs usually asymptomatic for three to four decades 
and reaches the stage of cirrhosis at a median age of about 45 years 
[Brunetto et al., 2002]. Thereafter cirrhosis progresses to end stage 
complications in about 25% of patients in about 10 years; recurrent hepatitis 
B exacerbations accelerate disease progression [Brunetto et al., 2002]. The 
virological and biochemical patterns of chronic anti-HBe positive hepatitis 
B vary from intermittently to persistently detectable viraemia and elevated 
ALT levels. In these patients, viraemic levels tend to be lower fluctuanting 
within the range 10
4
-10
7
 genomes/ml than those HBeAg positive (range 10
6
 
- 10
9
 gen/ml). In spite of an intermitting disease profile associated with 
frequent and sometimes long lasting remissions spontaneous recovery from 
anti-HBe positive chronic hepatitis B is very rare [Lok et al., 2001; 
Hadziyannis et al., 2005; Brunetto et al., 1989; Brunetto et aòl., 2002]. 
Persistent viral replication is a major cause of chronic liver damage and 
development of cirrhosis: in a cohort study after a mean follow-up of 10 
years about 50% of the patients with chronic hepatitis at baseline developed 
cirrhosis and persistently detectable HBV DNA was a factor independently 
associated with disease progression [Brunetto et al., 2002]. Further, 
cirrhosis development as an end point complication was associated with 
recurrent hepatitis exacerbations [Brunetto et al., 2002]. 
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Active carriers have a significantly increased risk of life-threatening 
liver complications such as hepatic decompensation, liver cirrhosis and 
hepatocellular carcinoma [Beasley, 1988]. HBV infection appears to play 
both an indirect (via liver cirrhosis) and direct role in hepatocellular 
carcinoma development: the mechanisms of direct HBV oncogenesis are not 
completely understood, nevertheless either integration of HBV genomic 
DNA into cellular chromosomes, with disregulation of cellular gene 
function and transactivating activity of some HBV proteins (such as HBx 
and HBs truncated forms) had been shown to alter cellular homeostasis. 
 
 
2.2.1 Diagnosis of HBV infection 
Virological diagnosis and monitoring of hepatitis B virus infection 
are based on serologic assays detecting specific anti-HBV antibodies, and 
assays that can detect, quantify or characterize the components of HBV viral 
particles, such as HBV DNA and various viral antigens. Polymerase chain 
reaction (PCR) based assays allow to detect, by specific molecular 
hybridisation of nucleic acid probes to the viral sequence target, less than 10 
copies/ml of virus starting from a serum or plasma sample of 0.2 ml 
[Raimondo et al., 2003]. The presence of HBV DNA in peripheral blood is 
a reliable marker of active HBV replication and reflect the viral activity 
within the liver. However, the diagnosis of the infection does not necessary 
imply that the liver is damaged by the virus. As described above, florid virus 
replication can persist for years without liver damage if the host's immune 
system does not react against viral antigens [Bonino et al., 1991b; Brunetto 
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et al., 1991b]. Liver disease begins as soon as immunotolerance is lost and 
the virus infected cells start to be eliminated, therefore hepatitis B represents 
an injurious way of recovering.  Serum IgM anti-HBc are detected in any 
form of liver disease caused by HBV, independent on the duration of virus 
infection. Serum anti-HBc IgM are usually detected with high titers during 
an acute hepatitis B, and with lower titers after the typical flare-ups of 
alanine aminotransferase (ALT) which occur in chronic hepatitis. These 
episodes of ALT flare up are preceded by an increase or reappearance of 
viraemia [Colloredo et al., 1992] followed by rapid decline, whereas the 
elevation of IgM anti-HBc persist for a longer period due to their extended 
half life.  
HBsAg has been recently shown to represent a new diagnostic tool in 
the management of HBV infection. HBsAg serum levels vary during 
chronic hepatitis B infection, becoming lower during the transition from the 
active to the inactive phase of HBV infection [Nguyen et al 2010; 
Jaroszewicz et al., 2010; Brunetto et al., 2010]. Recent findings confirm that 
serum HBV DNA and HBsAg levels provide complementary information 
on the status of HBV infection and  showed that the single point combined 
quantification of HBV DNA (<2000 IU/mL) and HBsAg (<1000 IU/mL) 
allows the identification of inactive carrier with a very high diagnostic 
accuracy (94.3%) that is comparable with that of 1 year monthly monitoring 
[Brunetto et al., 2010]. HBsAg serum levels were shown to correlate with 
intrahepatic covalently closed circular DNA (cccDNA) levels [Volz et al., 
2007] that vary in different patient populations but persist through all phases 
[Werle-Lapostolle et al, 2004]. 
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2.3 Treatment anti-HBV: Indications and Goals 
The guidelines from the American Association for the Study of Liver 
Diseases (AASLD) [Lok et al., 2009]  and the Asian-Pacific Association for 
the Study of the Liver (APASL) [Liaw et al., 2008] advocate treatment for 
patients with hepatitis B e antigen (HBeAg)–positive chronic hepatitis B 
virus infection with serum HBV DNA levels > 20,000 IU/mL and 
persistently elevated ALT levels (> 2 times the upper limit of normal (ULN) 
over a 3-6 month period). The updated normal ALT levels have been 
established at 30 U/L for men and 19 U/L for women [Prati et al., 2002]. 
According to the AASLD guidelines, the same HBV DNA and ALT 
criteria apply to HBeAg-negative patients, but treatment should also be 
considered in patients with normal ALT if the HBV DNA concentration is > 
2000 IU/mL and if they have a liver biopsy showing moderate to severe 
necroinflammation with or without fibrosis [Dienstag et al., 2008]. The 
APASL guidelines recommend to consider antiviral treatment for HBeAg-
negative patients with HBV DNA ≥ 2000 IU/mL and ALT levels 
persistently > 2 x ULN [Liaw et al., 2008]. 
According to the 2012 HBV guidelines of the European Association for 
the Study of the Liver (EASL), patients should be considered for antiviral 
therapy if they have HBV DNA levels > 2000 IU/mL, ALT levels > 1 x 
ULN, and a liver biopsy that shows moderate to severe necroinflammation 
or fibrosis, regardless of their HBeAg status. In addition, treatment may be 
initiated in patients with normal ALT levels if they have HBV DNA levels > 
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2000 IU/mL and a liver biopsy that shows moderate to severe 
necroinflammation or fibrosis. Immediate liver biopsy or therapy is not 
necessary in HBeAg-negative patients with persistently normal ALT levels 
and HBV DNA levels > 2000 IU/mL but < 20,000 IU/mL and no evidence 
of liver disease. Conversely, both HBeAg-negative and HBeAg-positive 
patients with ALT levels > 2 x ULN and serum HBV DNA > 20,000 IU/mL 
may initiate therapy without the results of a liver biopsy. 
Patients who are not candidates for immediate initiation of therapy 
should be closely monitored. Hepatitis B e antigen positive patients with 
HBV DNA > 20,000 IU/mL but normal ALT levels or an absence of 
necroinflammation on the liver biopsy (ie, so-called immunotolerant 
patients) should have their ALT levels measured every 3-6 months and 
should be regularly tested for the presence of HBeAg (approximately every 
6-12 months [Lok et al., 2009]. In HBeAg-negative patients with HBV 
DNA < 2000 IU/mL and normal ALT (ie, so-called inactive hepatitis B 
surface antigen carriers), ALT and HBV DNA levels should be reassessed 
every 3 months during the first year, with subsequent biannual assessments 
[Lok et al., 2009]. Patients with low levels of serum HBV DNA (< 2000 
IU/mL), as well as low levels of HBsAg (< 1000 IU/mL), may perhaps 
require less frequent monitoring due to a very low probability of disease 
reactivation [Brunetto et al., 2010]. 
Complete eradication of HBV from host hepatocytes cannot be 
achieved with currently available agents because of the persistence of HBV 
covalently closed circular DNA. The main goal of treatment for chronic 
HBV infection, therefore, is to halt the progression of liver inflammation to 
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fibrosis, cirrhosis, or hepatocellular carcinoma [Feld et al., 2009]. Because 
these outcomes typically do not occur until decades after active infection, 
surrogate outcomes are used as measures of therapeutic efficacy and 
success. Several independent studies have shown that lower levels of HBV 
DNA, as well as clearance of HBeAg and HBsAg, are associated with a 
lower risk of cirrhosis, hepatocellular carcinoma, and death [Iloeje et al., 
2006; Chen et al., 2006; Yang et al., 2002]. Therefore, the major endpoints 
of treatment are a reduction of HBV DNA to undetectable levels (virologic 
response), a loss of HBeAg with or without the appearance of antibodies to 
HBeAg (serologic response), a reduction of alanine aminotransferase to 
levels considered normal (biochemical response), and a reduction in liver 
necroinflammation with or without an improvement of liver histology [Lok 
et al., 2009]. Loss of HBsAg from serum, accompanied by the appearance 
of antibodies to HBsAg, is currently considered the optimal surrogate 
endpoint, although it is rarely achieved [Perrillo et al., 2006]. 
 
 
2.3.1 Interferons  
Interferons belong to the family of cytokines, products of nature 
polypeptide processed by different types of cells after appropriate stimuli 
that, by exerting a flow modular nature of other functional cells (target 
cells), evoke various and complex metabolic and biological responses. 
Interferons are a group of glycoproteins of molecular weight between 
15,000 and 20,000 Dalton (D); Interferons are processed by virus-infected 
cells and induce a state of antiviral resistance in other cells in the body. 
49 
 
To date 3 different classes of interferons, derived from distinct cell 
populations, are known: interferon alpha (or leukocyte) interferon beta (or 
fibroblast) and interferon gamma (or immune). The mechanism of the 
antiviral effect of interferons, still somewhat indefinite, resides in the 
induction of an antiviral state in the target cells. This depends on the 
synthesis of at least two cellular enzymes: the 2'-5'-oligoadenilatesintetase 
(2'-5'-A-polymerase) and the kinase protein (PK). The first promotes the 
activation of a ribonuclease that degrades the viral messenger RNA and the 
second providing the phosphorylation, with consequent inactivation, of the 
peptide that initiates the viral protein synthesis. Genetic engineering, with 
the recombinant DNA technology, has allowed to produce large quantities 
of highly purified interferons. Particularly, interferon alpha-2a (IFN-α-2a) 
and interferon alpha-2b (IFN-α-2b) are highly purified proteins with a 
molecular weight of about 19,000 D; each contain 165 amino acids, are 
produced by a recombinant bacterium (E. coli) and differ by a single amino 
acid. 
The distribution and metabolism of the interferons in the body are 
not completely known. Their elimination is primarily by renal excretion, 
although a small proportion of the drug is eliminated via the bile. The 
plasma half-life of recombinant interferon alfa is about five hours. 
The use of IFN-α has some limitations, as it is often burdened by side 
effects and poor tolerability. This treatment has been shown to induce 
seroconversion from HBeAg to antiHBe in approximately 30-40% of 
patients with HBeAg positive chronic hepatitis B and stop the disease in 
about 20% of patients with antiHBe. 
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A significant proportion (30-60%) of patients who respond to IFN 
can also have HBsAg loss, months or years after the treatment cycle. 
The pegylated interferon (PEG-Interferon, produced by a covalent bond 
with a branched molecule of methoxy-polyethylene glycol) is the ultimate 
formulation developed among the interferon alpha recombinants, 
characterized by a different pharmacokinetic that allows a slow elimination 
and a single weekly administration. 
Although treatment with PEG-interferon is effective in patients with 
advanced fibrosis and compensated cirrhosis, it is contraindicated in patients 
with decompensated liver disease because of the risk of worsening liver 
disease and infectious complications [Lok et al., 2009; Buster et al., 2007] 
Nucleos(t)ide analogue treatment is, therefore, the best option in this patient 
population, and use of agents with high potency and low risk of resistance is 
recommended by the American Association for the Study of Liver Diseases 
[Lok et al., 2009] and the European Association for the Study of the Liver. 
 
 
2.3.2 Lamivudine 
Lamivudine (2', 3' dideoxy tiacitidina) is an analogue L-nucleoside 
that phosphorylated to adenosine triphosphate (3TC-TP) competes with 
dCTP for incorporation into the nascent chain of HBV DNA. If embedded 
by the viral polymerase acts as a chain terminator [Conjeevaram et al. 
2003]. Lamivudine (LAM) is a high efficacy and tolerability drug but it may 
lead to the selection of HBV resistant variants (as previously described) 
during therapy. Several data has been published during the last decade 
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showing the yearly incremental probability of developing resistance in 
patients under LAM mono-therapy (figure 7). 
 
 
2.3.3 Adefovir dipivoxil 
Adefovir dipivoxil (ADV) is a second generation nucleotide 
analogue, an adenosine monophosphate that, once in the hepatocyte, 
become diphosphate after two phosphorylation reactions and in this form it 
can interact with the viral polymerase inhibiting the replication cycle by 
ending the nascent nucleic acid chain [Marcellin et al. 2005]. The ADV has 
proven to be an efficient drug with a good antiviral effect but lower than 
that of the lamivudine. It is effective against viral strains resistant to 
lamivudine and before the advent of the NAs third generation was the 
rescue drug in case of LAM therapy failure. The probability of developing 
HBV resistant mutants during the treatment is lower than LAM but still 
present with 29% of cumulative probability after 5 years of therapy (figure 
7). Moreover, because of its nephrotoxicity, adefovir must be administered 
in dose (10 mg/day) lower than all the other NAs and lower than that needed 
to achieve the maximum inhibitory effect of viral replication [Jannsen H 
2012]. 
 
 
2.3.4 Telbivudine 
Telbivudine (LdT) was approved for chronic hepatitis B viral 
infection in the United States in October 2006 and is indicated for patients 
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with compensated chronic HBV infection and with evidence of viral 
replication and either evidence of persistent elevations in aminotransferases 
or histologically active disease. Telbivudine has greater antiviral efficacy 
compared with lamivudine in both hepatitis B e antigen (HBeAg)–positive 
and HBeAg-negative chronic HBV infection [Lai et al., 2007] 
Despite the high potency of telbivudine, virologic response rates 
deteriorated over time due to the emergence of telbivudine resistance; 
indeed, telbivudine resistance mutations were found in up to 17% of patients 
after 2 years of therapy (Figure 7) [Zoulim et al., 2009]. Notably, 
telbivudine resistance mutations confer cross-resistance to lamivudine. 
Telbivudine, therefore, has limited application in the treatment of patients 
with chronic HBV infection. 
 
 
2.3.5 Entecavir 
Cyclopentyl guanosine analogue, entecavir (ETV) is a potent 
inhibitor of HBV reverse transcriptase. Entecavir functionally inhibits all 
the activities of the HBV Pol/Rt: (1) base priming, (2) reverse transcription 
of the negative strand from the pregenomic messenger RNA, and (3) 
synthesis of the positive strand of HBV DNA. Upon activation by kinases, 
the drug can be incorporated into the nascent viral DNA inhibiting the HBV 
Pol/Rt activity [Marcellin et al., 2005]. There are no significant adverse 
effects reported to date. Its antiviral efficacy is superior to that of LAM and 
ADV and in naive subjects shows a very low rate (1.2%) of resistance after 
5 years of treatment (figure 7). Different is the situation in LAM resistant 
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patients as they require higher doses of ETV because of the serious risk of 
resistance, that in this case, is 25% after 3 years of treatment [Balfour 1999, 
Yamanaka et al. 1999, De Man et al., 2001].  
 
 
 
2.3.6 Tenofovir 
Such as adefovir, tenofovir (TFV) is an acyclic nucleoside 
phosphonate and belong to the third generation of NAs. The TFV is a 
nucleotide analogue of adenosine monophosphate and act as a chain 
terminator when embedded in the nascent viral DNA. Approved for the 
treatment of HBV infection in the United States in 2008, tenofovir is 
indicated for the treatment of compensated chronic HBV infection in adults. 
It has demonstrated superior antiviral efficacy compared with adefovir in 
both HBeAg–positive and HBeAg-negative patients [Marcellin et al., 2008]. 
Recently, a large investigator-initiated study showed that 79% of patients 
who failed previous nucleos(t)ide analogue treatment achieved HBV DNA 
levels < 400 copies/mL after a median follow-up of almost 2 years of 
tenofovir therapy [Van Bommel et al., 2010]. This study also suggests a 
reduced antiviral effect of tenofovir in the adefovir-resistant population. To 
date, tenofovir resistance has not been detected in treatment-naive patients 
treated for up to 4 years (Figure 7) [Snow-Lampart et al., 2010] although 
viraemic patients were allowed to switch to a combination of tenofovir and 
emtricitabine at Week 72 [Heathcote et al., 2011; Heathcote et al., 2010; 
Marcellin et al., 2010]. 
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Figure 7. Cumulative incidence of HBV resistance against the five approved 
NAs for antiviral therapy (Adapted from: EASL Clinical Practice 
Guidelines: management of chronic hepatitis B - 2009). 
 
 
 
2.4 Nucleos(t)ide Analogues treatment monitoring and definition of 
antiviral response and resistance. 
The currently approved nucleos(t)ide analogues can adequately 
suppress HBV DNA levels, normalize alanine aminotransferase levels, and 
improve liver histology [Dienstag et al., 2009], but their antiviral efficacy is 
markedly reduced in patients who develop drug-resistant hepatitis B virus 
variants, resulting in virologic breakthrough, hepatitis flares, and a reduction 
in clinical benefits [Liaw et al., 2004]. To avoid emergence of viral 
resistance is therefore essential to successful antiviral therapy with 
nucleos(t)ide analogues. 
Persistent viral replication during antiviral therapy (measured by 
HBV DNA levels) is a major risk factor for the subsequent development of 
antiviral resistance [Zeuzem et al., 2009; Hadziyannis et al., 2006; Liaw et 
al., 2009b; Yuen et al., 2001]. Therefore, HBV DNA levels should be 
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monitored at least every 3-6 months with a sensitive assay (lower limit of 
detection of newest assays is < 20 IU/mL) in patients treated with 
nucleos(t)ide analogues according to the AASLD and the EASL guidelines. 
Current guidelines recommend treatment modification in patients with 
detectable HBV DNA levels after a predefined duration of treatment [ 
Zeuzem et al., 2009; Janssen et al., 2009; Lok et al., 2009]. Particularly, the 
European Association for the Study of the Liver guidelines have attempted 
to classify response patterns to nucleos(t)ide analogues and to advise 
treatment modification in suboptimal responders to prevent the development 
of resistance (Figure 8): 
- Complete virological responders are those patients who accomplish 
undetectable levels of HBV DNA within 48 weeks of therapy. These 
patients have a low probability of emergence of viral resistance. 
- Primary nonresponders are those patients with a suboptimal 
response, failing to achieve ≥ 1 log10 IU/mL drop in HBV DNA 
levels by 3 months after commencing therapy. 
- Partial response is defined as an on-treatment decline in HBV DNA 
of ≥ 1 log10 IU/mL but failure to achieve undetectable HBV DNA 
levels at Week 24 (for lamivudine and telbivudine) or Week 48 (for 
adefovir, entecavir, tenofovir). Different requirements have been set 
for lamivudine and telbivudine vs adefovir, entecavir, and tenofovir 
because of the lower barrier to resistance of lamivudine and 
telbivudine. 
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- Virologic breakthrough is defined as an increase in serum HBV 
DNA > 1 log10 above nadir after achieving a virologic response 
during continued treatment [Lok et al., 2009]. 
 
 
Figure 8. The different type of antiviral responses during the NAs antiviral 
therapy. Sequence analysis should be performed before the start of treatment 
and repeated, in case of detectable viraemia, every 6 months (LLOD = 
Lower Limit of Detection). 
 
 
 
2.5  Nucleos(t)ide Analogues Resistant Variants 
The resistant mutations locate on the HBV 
Polymerase/Retrotranscriptase region with codons rt204 and/or rt181 
involved in all the different class of drugs. Particularly rtM204I or V quasi-
species can be selected and emerge during Lamivudine treatment as primary 
resistance mutations [Ling R et al., 1996; Bartholomew M et al., 1997; Yeh 
C et al., 2000; Marcellin P et al., 2003]. Moreover, secondary/compensatory 
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mutations are often co-selected with the primary ones to generate multi-
mutational patterns affecting rescue therapies. The rtL180M + rtM204I or V 
is the most common resistant pattern selected during LAM treatment and in 
particular is the background for ETV resistance since the addition of only 
one more mutation among rtI169T, rtT184G, rtS202T, rtM250I or V is 
required. As entecavir resistance mutations has never been detected in naive 
patients, LAM treatment exposure and/or failure play a critical role in the 
clinical outcome [Tenney DJ et al., 2004; Colonno RJ et al., 2006; Zoulim 
et al., 2006; Villet S et al., 2007].      
The rtA181S or T or V mutations can be selected and emerge during 
Nas therapy and like the rtM204I or V are classified as primary resistant 
mutations. Interestingly, the rtA181 variants are also classified as cross 
resistant mutations since their ability to replicate in presence of both LAM 
and ADV [Fung SK et al., 2005; Yeon JE et al., 2006; Lacombe K et al., 
2006; Moriconi F et al 2007; Karatayli E et al., 2007].   
The rtN236T is also a primary resistant mutations although to date it 
has been found, in vivo, during ADV monotherapy failure only and rescue 
therapy worked fine with ETV or TFV [Angus P et al., 2003; 
Bartholomeusz A et al., 2006; Ratziu et al., 2006; Shim JH et al., 2009] 
(Figure 9). 
Recently, resistant variants has been detected, as minor viral 
populations, in naive patients sera also. Such a data has been obtained with 
high sensitive laboratory method. Indeed, considering the HBV high rate of 
mutation (0.9x10
-3
 base substitutions/site/year) and the estimated HBV 
production rate of at least 10
13
 virions/day [Whalley S et al., 2001], it was 
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probable to find several viral variants, the drugs resistance included, when a 
deep viral population study would be performed in HBV chronic infected 
patients. 
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2.6 Laboratory Method for the Identification of HBV Resistant 
Variants. 
Several laboratory methods have been developed over the years to help 
clinicians to optimize the treatment of CHB patients avoiding resistance: 
 Polymerase chain reaction (PCR) is a biochemical technology in 
molecular biology to amplify a single or a few copies of a piece of 
DNA across several orders of magnitude, generating thousands to 
millions of copies of a particular DNA sequence. The PCR is the 
method on wich many of the actual diagnostic assay are based on and 
relies, in particular, on thermal cycling, consisting of cycles of 
repeated heating and cooling of the reaction for DNA melting and 
enzymatic replication of the DNA. Primers (short DNA fragments) 
containing sequences complementary to the target region along with 
a DNA polymerase are key components to enable selective and 
repeated amplification. As PCR progresses, the DNA generated is 
itself used as a template for replication, setting in motion a chain 
reaction in which the DNA template is exponentially amplified.  
Most PCR methods typically amplify DNA fragments of up to 
~10 kilo base pairs (kb) requiring the following reagents: (i) DNA 
template that contains the DNA region (target) to be amplified; (ii) 
Two primers that are complementary to the 3' (three prime) ends of 
each of the sense and anti-sense strand of the DNA target; (iii) Taq 
polymerase or another DNA polymerase with a optimal working 
temperature at around 70 °C; (iv) Deoxynucleoside triphosphates 
(dNTPs; nucleotides containing triphosphate groups), the building-
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blocks from which the DNA polymerase synthesizes a new DNA 
strand; (v) Buffer solution, providing a suitable chemical 
environment for optimum activity and stability of the DNA 
polymerase; (vi) Magnesium (Mg2+), a divalent cation whose final 
concentration affect the yield of the reaction (DNA synthesis). 
The PCR method is a multistep process easily carried out today 
by automated thermal cycler. The different steps include: (i) 
denaturation, heating the reaction to 94–98 °C for 20–30 seconds to 
melt DNA template by disrupting the hydrogen bonds between 
complementary bases, yielding single-stranded DNA molecules; (ii) 
annealing, the reaction temperature is lowered to 50–65 °C for 20–40 
seconds allowing annealing of the primers to the single-stranded 
DNA template. Typically the annealing temperature is about 3-5 
degrees Celsius below the Tm of the primers used. Stable DNA-DNA 
hydrogen bonds are only formed when the primer sequence very 
closely matches the template sequence. The polymerase binds to the 
primer-template hybrid and begins DNA formation; (iii) 
extension/elongation, a temperature of 72 °C is commonly used at 
this stage where the DNA polymerase synthesizes a new DNA strand 
complementary to the DNA template strand by adding dNTPs that 
are complementary to the template in 5' to 3' direction, condensing 
the 5'-phosphate group of the dNTPs with the 3'-hydroxyl group at 
the end of the nascent (extending) DNA strand. The extension time 
depends on the length of the DNA fragment to be amplified.  
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 After PCR discovery, several variants of this method has been  
developed. Here we are going to briefly describe two of the most 
used variants: Nested PCR and Allele Specific PCR. The former is a 
double PCR increasing the specificity of DNA amplification but 
above all increasing the yield of the reaction. A small (2ul) volume of 
the first PCR is amplified in a second roud using two internal primers 
encompassing nucleotide regions present on the DNA target. 
The Allele Specific is based on single-nucleotide polymorphisms 
(SNPs) (single-base differences in DNA). It requires prior knowledge 
of a DNA sequence, including differences between alleles, and uses 
primers whose 3' ends encompass the SNP. PCR amplification under 
stringent conditions is much less efficient in the presence of a 
mismatch between template and primer, so successful amplification 
with an SNP-specific primer signals presence of the specific SNP in a 
sequence.  
 Direct PCR-based DNA sequencing (DS) is to date the gold standard 
for HBV mutations analysis. The method involves DNA 
denaturation, annealing, and elongation. During elongation, DNA 
polymerase randomly incorporates deoxynucleotides or 
dideoxynucleotides that have been labeled with different 
fluorochromes, resulting in chain elongation or termination, 
respectively. Chains of different lengths are therefore generated, 
each ending with a labeled nucleotide. The amplicons are then 
migrated in a capillary system that separates them according to their 
lengths. Bioinformatic software measures the fluorescence peak at 
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each position of the analyzed sequence and identifies the 
corresponding dideoxynucleotides to determine a consensus 
sequence. The presence of multiple peaks at the same position 
indicates a mixed sequence.  
Critical issues concerning the DS are based on the fact that 
HBV, like other viruses able to establish chronic infections (ie HIV, 
HCV) behave as quasispecies, complex mixtures of genetically 
related but distinct viral populations in equilibrium in a given 
replicative environment. Therefore, at any given time, patients carry 
a large number of different viral genome sequences. The classic 
sequencing techniques can only identify the consensus sequence of a 
viral quasispecies at a given time point, whereas intermediate and 
minor viral populations go undetected if not present in at 20% of the 
total viraemia. In addition, this approach cannot link different 
substitutions present in the same viral variant or distinguish 
substitutions present in different variants. 
For all the reasons above described, Direct PCR-based DNA 
sequencing is not the recommended method to characterize minor 
viral populations within patient quasispecies [Shaw T et al., 2006]. 
Direct sequencing after cloning can overcome this problem, but 
analysis of large numbers of clones is required and makes this 
method too cumbersome and time consuming for a systematic 
application to a diagnostic routine [Pallier et al., 2006]. 
 An alternative method, based on reverse hybridization, is the Line 
Probe Assay (INNO-LiPA) where different mutant probes, spotted 
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on nitrocellulose strips, are incubated with HBV polymerase 
fragment amplified from serum sample. INNO-LiPA is the most 
commonly used technique for the analysis of HBV RVs quasispecies 
in clinical practice and require a total viremia >10E+03 cp/ml to 
detect 5-10% of mutant prevalence. The advantage of this technique 
is the early time in resistant variants detection compare to DS. The 
major limit is that only the known RVs can be detected and several 
important secondary / compensatory mutations are missing, 
particularly those associated to entecavir resistance [Hussain et al., 
2006; Jardi et al., 2009]. 
 New promising methods has been developed during the last years to 
increase sequencing capacity while generating clonal sequences. 
Classified as Next Generation Sequencing (NGS), these methods are 
actually the most powerful to analyze and study viral quasispecies. 
The NGS methods use a 3 step sequencing process: library 
preparation, DNA capture and enrichment, and sequencing. In 
library preparation, DNAs of appropriate lengths are prepared and 
labeled with the primers required for subsequent isolation and 
sequencing. DNA is then captured, and clonal DNA is enriched. The 
DNA is then sequenced, via polymerization combined with detection 
based on pyrophosphate (pyrosequencing), H
+
 ions (pH variation) or 
fluorescence, or ligation combined with fluorescence detection. The 
detected signals are transformed into readable sequences by an 
integrated browser and specific software to produce biologically 
relevant information. 
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The NGS methods are susceptible to generating sequencing 
errors and to date there is still some controversy about the actual 
error rates of these methods, so prospective assessments are required 
by independent investigators. Moreover, NGS methods generate 
unreadable sequences (called junk data) at variable rates. This is 
associated with an over cost but not with lower quality final results 
because these sequences can be easily identified and removed. False-
positive or false-negative results for substitutions have been also 
reported and are easily corrected when the sequencing depth is high, 
as in Genome Wide Association Study or gene expression profiling 
studies, but are problematic for studies of rare variants [Harismendy 
O et al., 2009; Suzuki S et al., 2011]. The relatively short read-
length of the sequences obtained with the NGS methods is another 
deal that can affect analysis and studies on variants. The maximum 
length of individual sequencing runs are in fact shorter (maximum 
400bp, primers included) than those obtainable with DS method 
(≈700bp). 
However, to date, the main need in the field of NGS is for 
bioinformatic tools to analyze NGS sequences in the context of viral 
infections. Complex analyzing software might be suitable for 
research purposes, but clinicians will require bioinformatic tools able 
to translate millions of generated sequences into simple and 
clinically relevant information on which therapeutic decisions can be 
made. 
66 
 
 Real-Time PCR is a recently developed methods following the 
general principle of polymerase chain reaction; its key feature is that 
the amplified DNA is detected as the reaction progresses in real 
time. This is a new approach compared to standard PCR, where the 
product of the reaction is detected at its end. A common method for 
detection of products in real-time PCR consist of a sequence-specific 
DNA probe labeled with a fluorescent reporter at one end and a 
quencher of fluorescence at the opposite end of the probe. The close 
proximity of the reporter to the quencher prevents detection of its 
fluorescence; after specific hybridization of the probe with its 
complementary DNA target, breakdown of the probe itself by the 5' 
to 3' exonuclease activity of the Taq polymerase breaks the reporter-
quencher proximity and thus allows unquenched emission of 
fluorescence, which can be detected after excitation with a laser. An 
increase in the product targeted by the reporter probe at each PCR 
cycle therefore causes a proportional increase in fluorescence due to 
the breakdown of the probe and release of the reporter. 
Fluorescence is detected and measured in a real-time PCR 
machine, and its geometric increase corresponding to exponential 
increase of the product used to determine the threshold cycle (CT) in 
each reaction. Real-Time PCR account for high sensitivity and 
specificity and its application to the identification of HBV resistant 
variants showed interesting results detecting quasispecies down to 
0.1% or lesser. The main disadvantages of Real-Time PCR are the 
set up of a specific assay including designing of the primers and 
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probe, the fluorophores labeling and the development of a 
sophisticated software and algorithms for the calculation of the target 
quantity. All these phases are also cost affecting the available 
commercial kit. In addition, studies performed up to date on HBV 
resistant variants developed and used methods requiring high 
viremia levels >10E+04 cp/ml to reach high sensitivity and to avoid 
aspecific amplifications [Lupo et al., 2009; Zhao et al., 2010; Liu et 
al., 2011]. 
 
 
2.7      Aim of the study 
Antiviral therapy for HBV has reached today a high safety level with 
the use of third generation NAs (Entecavir, Tenofovir). Nevertheless, none 
of the drugs available today against HBV is able to eradicate the virus from 
the epatocytes and long-term therapy continue to be the treatment of choice. 
For this reason, the risk of selection and emergence of resistant variants is 
not averted, particularly in patients previously treated with NAs first 
generation and treatment failure experienced.  
High sensitive laboratory methods have shown the presence of 
resistant variants, at low concentration level, in naive patients but very few 
or nothing is known about their influence on the response to antiviral 
treatment. Thus, a better understanding of the dynamics of drug resistants 
variants could contribute to the improvement in the management of CHB 
pts. 
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The aim of our study was to develop a sensitive and specific assay to 
detect rt204 and rt181 HBV resistant variants in low viraemic sera 
(<10E+04 cp/ml) and to investigate the RVs early dynamics during 
lamivudine treatment. Thus, considering the   
 
 
2.8 Patients and Methods 
2.8.1 Sera Panel and Criteria for patients inclusion 
A retrospective panel of 73 serum samples from 15 CHB patients 
(median age 56 years, range 27 – 73 years; 11 males, 4 female), treated with 
LAM from the year 2000 at the Hepatology Unit of Pisa University 
Hospital, was tested (Table 1). Patients (pts) were selected from a large 
LAM treated cohort monitored in our clinic and were followed-up for a 
median period of 24 months (range 4 – 143). The selection was done 
according to three main different viral response profiles observed during 
treatment: five pts had Complete Viral Response (CVR), defined as HBV 
DNA < 200 copies/mL at month 6 or earlier, that was maintained 
throughout the follow-up; six pts had Resistance After Complete Viral 
Response (RACVR), defined as a rebound of HBV DNA > 200 cp/ml in 
patients who showed CVR; four pts had Incomplete Viral Response (IVR), 
defined as HBV DNA > 200 cp/ml during the entire follow-up. Pre-
treatment serum and on treatment serum samples were tested in every 
patient during the first year of treatment. One or more samples were 
analysed during the further of follow up in 2 IVR and 5 RACVR pts.  
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Eight out of 15 pts had a histological diagnosis of chronic hepatitis, 3 
pts had chronic hepatitis with cirrhosis, 4 pts had hepatocellular carcinoma. 
Antibodies against HBeAg were present in all the pts but one, positive for 
the HBe antigen.  
Patients were monitored for liver function tests and HBV DNA 
levels monthly during the first year of therapy and every 3 months 
thereafter. HBV DNA levels were measured by Roche's COBAS® 
AMPLICOR HBV MONITOR Test, linear dynamic range 200 – 200000 
cp/ml,  and by Roche’s COBAS TaqMan 48, linear dynamic range 20 – 
1,7E+08 UI/ml (1UI/ml equivalent to 5,82 cp/ml). Clinical evaluations were 
performed every 3 months, ultrasound every 6 months in patients with 
cirrhosis, yearly in pts with chronic hepatitis. All the patients were negative 
for antibodies against hepatitis C virus (HCV), hepatitis D virus (HDV) and 
human immunodeficiency virus (HIV).  
 
Table 1. Demographic and clinical data 
 
 
 
 
 
 
2.8.2 HBV DNA extraction and amplification 
Viral DNA was extracted from 200 µl of serum samples with 
QIAamp MinElute Virus Spin Kit (QIAGEN, GmbH) according to the 
 
Median Age (range) 56 years (27-73 years)
Male/female 10/4
Chronic hepatitis/cirrhosis/liver
transplant 8/3/3
Median follow-up (range) 41 months (4-143 months)
Median ALT baseline (range) 138 U/L (45-558 U/L)
Genotype A/D 3/11
HBeAg-positive/HBeAg-negative 1/13
Median HBV-DNA baseline
levels (range)
3,2E+08 cp/ml (4,7E+04-
6,0E+08 cp/ml)
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manufacturer protocol. The HBV DNAs were finally resuspended in 50 µl 
of distilled water and stored at -20°C. Five microliters of extracted DNA 
were used to amplify the HBV RT region in a 50 µl reaction volume 
containing Buffer 1x [(67 mM TrisHCl (pH 8.7), 16 mM (NH4)2SO4)], 2.0 
mM MgCl2, 0.1 mM dNTPs, 2 U Dream Taq polymerase (Fermentas) and 
0.25 µM of each HBV universal primers, Pol1s nt 412-432 5’-
CCTGCTGCTATGCCTCATCTT-3’ and Pol4as nt 1058-1033 5’-
GGCATTAACGCAGGATAWCCACATTG-3’. The first round PCR cycle 
profiles was: pre-heating 3 min at 94ºC, 40 cycles including denaturation 30 
sec at 94ºC, annealing 30 sec at 55ºC and extension 30 sec at 72ºC, followed 
by 7 min at 72ºC. Negative samples after first round PCR were amplified in 
nested PCR using internal HBV universal primers Pol2s nt 449-469 5’-
GACTATCAAGGTATGTTGCCC-3’ and Pol181as and a thermal profile 
like the first round but for 20 cycles. Five microliters of PCR products were 
analyzed by ultraviolet fluorescence after ethidium bromide staining in a 2% 
agarose gel. 
 
2.8.3 Direct Sequencing 
PCR products were purified by Ethanol precipitation protocol 
(Beckman Coulter) and directly sequenced by chain terminator method 
using CEQ 8000 Dye Terminator Cycle Sequencing Quick Start Kit 
(Beckman Coulter); briefly 2µl of purified template were added to 8.0 µl of 
DTCS Quick Start Master Mix, 4.0 µl of 1.6 µM primer (POL2s and 
POL181as) and 6.0 µl of H2O. Thermal cycling profile was 30 cycles of 20 
sec at 96ºC, 20 sec at 50ºC, 4 min at 60ºC followed by holding at 4ºC. 
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Sequencing was carried out using a CEQ 8000 XL analysis System 
(Beckman). Alignment of nucleotide and amino acid sequences were 
performed with CLUSTAL W program at npsa-pbil.ibcp.fr/, NPS@: 
Network Protein Sequence Analysis (Combet C et al., 2000). 
 
 
2.9 Results 
2.9.1 Development and standardization of Allele Specific PCR for drug 
resistant mutants: Standards 
A total of 9 constructs containing the HBV wild-type and the 8 
different mutations causing resistance associated amino acid substitutions at 
codon rt181 and rt204 were generated. Particularly the 8 nucleotide 
mutations were responsible for rtA181S, rtA181T, rtA181T* (sW172stop), 
rtA181V, rtM204I (codon ata), rtM204I (codon atc), rtM204I (codon att), 
rtM204V (Table 2). We cloned a 647 bp fragment encompassing the B-E 
dominions of HBV RT region (412 to 1058 bp) from sera samples of 7 CHB 
NAs therapy failure patients. They were used as reference standards for the 
standardization and optimization of the assay. Briefly, serum HBV DNA 
was amplified using HBV universal primers POL1s and POL4as in PCR 
mixture and cycle profile as previously described. When HBV DNA level 
was below 10E+04 IU/ml, a nested PCR technique with HBV universal 
primers Pol2s and Pol181as was used to amplify a 540 bp region including 
the HBV RT B - E catalytic domains. The PCR products were ligated to 
pGEM vector (Promega) and cloned into JM109 competent cells. 
Transformants were grown on ampicillin plates and clone screening for RVs 
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was performed by sequencing after DNA extraction and reamplification by 
PCR. Approximately 20 clones per sample were sequenced with primers 
Pol2s and Pol181as. 
The DNA plasmids containing the reference standards were 
quantified spectrophotometrically and stocked at final concentration of 
10E+10 cp/ml. Ten fold serial dilutions of the stocks were prepared to 
generate standard curves with mixtures composed by every single mutant 
and the HBV wild-type. Mixture stocks were prepared in ratios of 1/10, 
1/100, 1/1000, 1/10000 at final concentration of 10E+04 cp/ml. 
 
Table 2. The 8 different nucleotide mutations causing resistance by amino 
acid substitutions at codon rt181 and rt204. 
 
 
 
* Premature stop codon on HBsAg coding frame 
 
2.9.2 Allele Specific Resistant Variant PCRs: strategy and primers 
design 
The Allele Specific PCR followed by emiNested PCR was the 
method we decided to develop combining specificity and sensitivity. As the 
8 standards representing the different RVs at codon rt181 and rt204 were 
obtained, eight specific primers for each RV were designed (Table 3) and 
tested separately in the standard mixtures prepared as described in the 
Standard session. In every RV specific primer, a mismatch was introduced 
at position 3 or 4 from the 3’-end to increase the specificity of the 
amplification [Flichman et al., 2005]. The 4 rt181 RVs specific primers 
codon Wt aa Wt aa position aa RV codon RV
gct A 181 S tct
gct A 181 T act
gct A 181 T* act
gct A 181 V gtt
codon Wt aa Wt aa position aa RV codon RV
atg M 204 I* ata
atg M 204 I atc
atg M 204 I att
atg M 204 V gtg
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were coupled with HBV universal primers Pol4as and Pol181as in first 
round and eminested PCR respectively. The 4 rt204 RVs specific primers 
were coupled with HBV universal primers Pol1s and Pol2s in first round 
and eminested PCR respectively (figure 10). Five microliters of standard or 
extracted DNAs were amplified by Allele Specific Resistant Variant PCRs 
(ASRVPCR) in a 50 µl reaction volume containing Buffer 1x, 1.0 mM 
MgCl2, 0.6 mM dNTPs, 5 U Hot start Taq polymerase (QIAGEN) and 0.25 
µM of each primer. Different ramped (‘touchdown’) cycle profiles for the 
different RVs specific primers were used to achieve the best sensitivity and 
specificity for the Allele Specific PCR method [Grace S et al., 1994]. In 
particular, the first round amplifcation conditions were: pre-heating 15 min 
at 94ºC, 30 - 40 cycles including denaturation 30 sec at 94ºC, annealing 30 
sec at 53 - 61ºC (-1°C per cycle in the first 5 cycles) and extension 30 sec at 
72ºC, followed by 5 min at 72ºC. Two microliters from the first round were 
amplified in a 50 µl reaction volume containing Buffer 1x, 2.4 mM MgCl2, 
0.58 mM dNTPs, 5 U Hot start Taq polymerase (QIAGEN) and 0.25 µM of 
each primer. The cycle profiles for eminested PCR had similar conditions 
but were not a touchdown and lasted for 20 cycles (Table 4). Finally, 7 
microliters of PCR products were analyzed by ultraviolet fluorescence after 
ethidium bromide staining in a 2% agarose gel. 
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Table.3 Primers used in the study for classic PCR, Allele Specific PCR and 
Direct Sequencing              
HBV Primers nt sequence
Position 
(EcoRI ref)
Universal
Pol4as 5’-GGCATTAACGCAGGATAWCCACATTG-3’ 1058-1033
Pol181as 5’-GACCCACAATTCKTTGACATACTTTCC-3’ 1006-980
Pol1s 5’-CCTGCTGCTATGCCTCATCTT-3’ 412-432
Pol2s 5’-GACTATCAAGGTATGTTGCCC-3’ 449-469
rt181 RVs specific
rt181S 5’-CTCCAGCCCGTTTCTGHAGT-3’ 651-670
rt181T* 5’-CTCCAGCCCGTTTCTGHAGA-3’ 651-670
rt181T 5’-CTCCAGCCCGTTTCTGYACA-3’ 651-670
rt181V 5’-TCAGCCCGTTTCTCHAGGT-3’ 653-671
rt204 RVs specific
Rt204I*(ata) 5’-CCCAATACCACATCAGCT-3’ 758-747
Rt204I (atc) 5’-CCCAATACCACATCACCG-3’ 758-747
Rt204I (att) 5’-CCCAATACCACATCAACA-3’ 758-747
Rt204V 5’-CCCAATACCACATCATCAAC-3’ 758-745  
* Premature stop codon on HBsAg coding frame 
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2.9.3 Specificity and Sensitivity of the method 
To set up amplification profile of Allele Specific Resistant Variant 
PCR, every single standard (n = 8) representing a RV at codon rt181 or 
rt204 was mixed with HBV wild type and selectively amplified with the 8 
different specific primers.  
To avoid aspecific amplification different ramped (“touchdown”) 
cycle profiles were used during first round of ASRVPCR for every RVs 
specific primers. Particularly, a common backbone profile for denaturation 
and elongation phase was maintained: 95°C for 30 seconds and 72°C for 45 
seconds respectively. A similar strategy was used in the eminested PCRs 
excepting for the touchdown option. The best results according to specificity 
and sensitivity could be obtained modifying the annealing temperature and 
the number of cycles of the thermal profiles. All the final annealing 
temperature and number of cycles are resumed in Table 4. Using those 
profiles the specific primers for mutant rtA181S and rtA181T could detect 
10 copies of the resistant variant construct on a background of 10E+04 
copies of wild-type (Figure 11A). Similar results were obtained for mutant 
primers rtA181T* (stop codon in S gene) and rtA181V (data not shown). 
The specific primers for mutant rtM204I (ata) and rtM204I (att) could detect 
100 copies of the resistant variant construct on a background of 10E+04 
copies of wild-type (Figure 11B). Similar results were obtained for mutant 
primers rtM204I (atc) and rtM204V (data not shown).  
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1-Wild type 1E+04 cp/ml
2-A181S 1E+01cp / Wild type 1E+04cp (fold 3)
3-A181S 1E+02cp / Wild type 1E+04cp (fold 2)
4-A181S 1E+03cp / Wild type 1E+04cp (fold 1)
5-A181S 1E+04 cp/ml
1      2       3      4      5
1-Wild type 1E+04 cp/ml
2-A181T 1E+01cp / Wild type 1E+04cp (fold 3)  
3-A181T 1E+02cp / Wild type 1E+04cp (fold 2)
4-A181T 1E+03cp / Wild type 1E+04cp (fold 1)
5-A181T 1E+04 cp/ml
1       2       3       4      5
A)
 
1-Wild type 1E+04 cp/ml
2-M204I (att) 1E+01cp / Wild type 1E+04cp (fold 3)
3-M204I (att) 1E+02cp / Wild type 1E+04cp (fold 2)
4-M204I (att) 1E+03cp / Wild type 1E+04cp (fold 1)
5-M204I (att) 1E+04 cp/ml
1-Wild type 1E+04 cp/ml
2-M204V 1E+01cp / Wild type 1E+04cp (fold 3)
3-M204V 1E+02cp / Wild type 1E+04cp (fold 2)
4-M204V 1E+03cp / Wild type 1E+04cp (fold 1)
5-M204V 1E+04 cp/ml
1      2       3       4      5
1       2       3       4      5
B)
 
Figure 11. Selective amplification of RVs end point diluted and mixed with 
HBV wild-type. A) Sensitivity and specificity for primers rtA181S and 
rtA181T are shown. B) Sensitivity and specificity for primers rtM204I and 
rtM204V are shown. 
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2.9.4 Clinical validation of the assay and early dynamic study on a sera 
panel from patients treated with LAM. 
A total of 73 serum samples from 15 CHB LAM treated patients 
were tested with Allele Specific for Resistance Variants technique and the 
Direct Sequencing was used as a comparator.  
 
Analysis on CVR group 
In each of 5 Complete Viral Response patients (pts n. 2, 3, 12, 13, 
14) 3 or 4 sequential samples collected at pre-treatment time and during the 
first 6 months of therapy were tested and no RVs were detected with 
ASRVPCR nor with DS (table 5).  
 
Analysis on RACVR group 
In 6 Resistance After Complete Viral Response patients (pts n. 1, 4, 
5, 6, 9, 11) a total of 33 sera, collected at pre-treatment time and during the 
follow-up were analyzed. Direct sequencing was firstly performed at the 
time of virological rebound and RVs were identified in all the cases: the 
rtA181S, rtA181T, rtM204I (codon att) and rtM204I (codon atc) were 
present in patient n. 11, 6, 1 and 5 respectively; the rtM204V was detected 
in patient n. 4 and 9. Moreover, the secondary/compensatory mutation 
rtL180M could be identified in all the sequences where a rtM204 resistant 
variant could be found. 
The pre-treatment serum and sequential samples of the RACVR pts 
were tested with ASRVPCR using the primer specific for the resistant 
variant previously identified by DS. Particularly, the mutant rtA181S was 
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present in all the samples tested of pt n. 11; in the pre-treatment serum, 
when total viraemia was 4.7E+04 cp/ml, during the LAM responding time 
(HBV DNA < 200 cp/ml) and at the virological rebound when viral load 
was 1.0E+04 cp/ml. The rtA181T and rtM204I (att) were only detected at 
the time of virological rebound in pt n. 6 and n. 1 respectively (table 5). In 
pt n. 5 the rtM204I (atc) could be detected for the first time at month 6 of 
therapy when viral load was 1.9E+04 cp/ml and its presence was confirmed 
in the subsequent samples at month 13 and 16 when viraemia was 6.0E+03 
and 3.3E+03 cp/ml respectively. Unexpectedly the rtM204I was not 
detected in the next available sample, month 25 when HBV DNA was low 
but still detectable with 300 cp/ml. That resistant variant was amplified 
again at month 41, when viral load was < 200 cp/ml and at the viral rebound 
time, month 51 with HBV DNA = 1.4E+03 cp/ml (table 5). The rtM204V 
was present in pt n. 4 in the pre-treatment sample when viral load was 
6.0E+05 cp/ml and in all the other samples tested, with a viraemia ranging 
from < 200 to 2.4E+03 cp/ml, but one at month 1 with HBV DNA = 
1.0E+03 cp/ml. The rtM204V was also detected at pre-treatment and at 
virological rebound time of pt n. 9 (table 5). The Direct Sequencing 
performed on samples of RACVR patients n. 1, 4, 5, 6 and 9 didn’t identify 
any RVs at pre-treatment time nor in the follow up sera preceding 
virological rebound. Differently, in pt n. 11 the DS detected a mixed 
rtA181A/S population after 1 month of treatment and thereafter.  
Analysis on IVR group 
In patients n. 7, 8, 10 and 15, IVR grouped, the Direct Sequencing 
was performed at first in the last follow-up sera available to investigate the 
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cause of the incomplete viral response and, resistant variants could be found 
in all the cases. In particular, pt n. 7 showed rtM204V and that mutation was 
also present in patient n. 8 and n. 15 along with (mixed population) rtM204I 
(att) and rtA181V respectively. In patient n. 10 the DS detected rtM204I 
(att), mixed with wild-type population, since the pre-treatment serum. The 
rtL180M mutation could be found as well, associated to the rtM204 
mutations. A total of 23 samples including the pre-treatment and follow up 
sera of 4 IVR pts were tested by ASRVPCR and DS as for the RACVR 
group. The rtM204V and rtM204I (att) variants were amplified by 
ASRVPCR in all the samples of pts n. 7 and 10 respectively (table 5). In 
patient n. 8, the rtM204V was detectable in all the samples while the 
rtM204I (att) could be amplified in the pre-treatment serum, HBV DNA = 
4.0E+06 cp/ml, but not later, at month 1 and 3 having viral load of 2.8E+05 
and 5.6E+05 cp/ml respectively. The rtM204I (att) could be detected again 
at months 5, 8 and 10 (end of follow-up, EOF) with increasing viraemia 
levels from 6.0E+04 to 2.0E+06 cp/ml. The rtA181V was detected in pt n. 
15 in the pre-treatment serum when viral load was 9.6E+05 cp/ml and, 
intermittently, in other 4 out of 8 follow-up samples tested, where viraemia 
levels ranged between 3.3E+02 and 1.5E+03 cp/ml (table 5). The rtM204V 
could also be amplified in pt 15 but only at month 10 of therapy (EOF). The 
comparator DS performed on IVR patients sequential sera revealed a mixed 
viral population, wild-type/rtM204I (att), in the pre-treatment sample of pt 
n. 10 and the RV was detected as the prevalent one in the following samples 
of the same patient. The DS found no resistant variants in pre-treatment 
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samples of the remaining IVR patients nor during the follow-up samples but 
in the EOF as previously described (Table 5). 
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2.9.5 ASRVPCRs product extensive analysis by sequencing method: 
some preliminary results 
Pre-treatment and EOF sera of 2 RACVR (n. 4, 9) and 3 IVR 
patients (n. 7, 8, 10), were sequenced, after ASRVPCR, with Pol2s primer 
to extensively characterize the Pol/Rt region of the amplicon obtained 
(figure 10). In all the patients, analyzed in this session, but number 10, the 
Pre-treatment sequences showed no additional mutation associated to the 
rtM204I or V already identified with ASRVPCR. Patient n. 10 showed a 
mixed viral population rtL180L/M detected, as previously described, with 
the Direct Sequencing method also.  
In all the patients, sequences obtained by the EOF amplicons showed 
the rtL180M mutation with no other RV or secondary / compensatory 
mutation. 
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3. Discussion. 
Antiviral therapy for HBV has been improved in the last years with 
the use of powerful and high genetic barrier nucleos(t)ide analogs 
(Entecavir, Tenofovir). The rates of treatment failure associated to the 
selection and emergence of resistant variants (RVs) showed to be very low 
after 5 years of ETV administration (1.2%) or 4 years of TFV (0.0%) 
treatment in naive patients [Tenney et al., 2009; Snow-Lampart et al., 
2010]. Despite these improvement, the HBV eradication from the epatocytes 
remain to date an unreached goal and long-term therapy with NAs is 
required to avoid recurrence of viral replication and disease reactivation. 
Therefore the risk of emerging drug resistant mutant and treatment failure is 
not completely abolished, even using ETV or TFV, particularly in patients 
pre-exposed to the first generation of NAs and in particular groups of 
patients like the immunocompromised in whom undetectability of viraemia 
may be difficult to achieve (Zoulim et al., 2009; Moriconi et al., 2007) 
increasing the risk of RVs selection.  
The aim of our study was to develop a high sensitive and specific 
assay detecting Resistant Variants at the most important HBV codons 
involved in drug resistant mutations: rtA181 and rtM204. We aimed to set 
up the method in selective amplification of the RVs in a range of low total 
viraemia (1.0E+01 - 10E+04 cp/ml), where none of the actual available 
method are working properly because of scarce sensitivity (Direct 
Sequencing, INNO-LiPA) or lack of specificity (Real Time PCR, Next 
Generation Sequencing).  
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We decided to develop a combination of two different PCR methods, Allele 
Specific PCR and Nested PCR, to achieve the specificity and sensitivity 
required.  
We succeeded in our purpose designing and using 8 specific primers 
in eminested single tube PCRs and dedicated ramped (‘touchdown’) cycle 
profiles. Our methods, high sensitive in-house Allele Specific Resistant 
Variant PCRs (ASRVPCR), were firstly developed testing standard curves 
made by mixtures of RVs and Wild-Type HBV clones.  
Optimal results were obtained in therm of specificity and sensitivity 
with the detection of at least 1% of mutant clones in 10E+04 cp/ml of total 
viraemia for every RVs. Sensitivity was even lower (0.1%) for primers 
encompassing the rtA181 mutations (Table 4). Such divergence could be 
due to the different specific primers that had to be forcedly designed in the 
position where the 3’-end locate on the resistant nucleotide mutation. That is 
the  peculiarity of the Allele specific assay to have specificity but at the 
same time may be a disadvantage for sensitivity allowing very few chances 
of primer modification to improve the yield of the reaction. 
The high specificity of our assay combined with optimal specificity 
prompted us to proceed to the next step of our project: the study of the early 
dynamics of drug resistant quasispecies on a sera panel of CHB patients 
treated with LAM. 
The Allele Specific PCRs for HBV rtA181 and rtM204 codons 
showed no RVs in the Complete Viral Response group. On the contrary, 
resistance variants were amplified before the treatment start in sera of 7 out 
of 10 patients who experienced therapy failure (RACVR + IVR). 
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Particularly, resistant quasispecies were found in 3 out of 6 RACVR pts and 
in all the 4 IVR pts, showing a different distribution among the different 
groups of patients. Moreover, the application, in 4 pts (2 RACVR + 2 IVR), 
of the sequencing method to the ASRVPCR products showed the addition of 
the rtL180M secondary / compensatory mutation to the rtM204 variants 
during the follow-up. Another IVR patient (n. 10) showed the rtL180M in 
both the pre-treatment and the EOF samples. These data suggest that, in our 
cohort, the RVs as primary resistant mutations can circulate in CHB naive 
patients and their presence can affect the LAM treatment, particularly when 
the rtL180M is acquired.  
The presence, as minor population, of drug resistant quasispecies in 
CHB naive patients has been already demonstrated in previous studies using 
several highly specific methods but all of them requiring levels of HBV 
DNA > 10E+04 cp/ml (Lupo et al., 2009; Fung et al., 2009; Zhao et al., 
2010) or an intense work screening hundreds of HBV clones (Pallier et al., 
2006). Our method proved to be specific and high sensitive (10-100 cp/ml) 
in a viraemia range of 10E+01 - 10E+04 cp/ml. In addition, the sequencing 
of the ASRVPCR product can reveal information about other important 
mutations locating on the HBV Pol/Rt region including the B dominion and 
the surrounding nucleotides like the A determinant (overlapping S gene) for 
a deep and extensive analysis of the RV strain.  
Today, in clinical practice of CHB patients, those drugs have been 
replaced, at least in Western Countries, by the more efficacy NAs third 
generation but their use is still wide in Asiatic CHB patients and for 
prophylaxis in particular group of patients like those undergoing organ 
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transplantation. In fact in treatment-naive patients receiving a donor liver 
HBcAb positive, the adoption of long-therm combined prophylaxis with 
lamivudine and anti-HBs immunoglobulin is recommended by the Italian 
Guidelines [Marzano et al., 2007]. 
Lamivudine is also administered in HBV inactive carrier patients 
undergoing immunosuppressive therapy or anti-tumoral chemotherapy since 
reactivation of HBV replication is frequently associated to 
immunocompromised conditions. 
Another group of patients in wich ASRVPCRs could be used is the 
LAM treatment failure expericed patients  going to be  affected by patterns 
of resistance based on rtM204 and rtA181 variants.  and help clinicians in 
the tailoring and optimization of the treatment for CHB patients, HBV 
infected OLT and immunocompromized patient, from the start and the on-
going phases where HBV DNA could persist at low level. 
In conclusion, whether confirmed in a larger cohort of patients, such 
a highly sensitive assay for the detection of Resistant Variants could warrant 
a safer use of NAs first/second generation like lamivudine, adefovir and 
telbivudine, prolonging their life in the HBV treatment in favour of a cost 
effective therapy regimen.   
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3 HEPATITIS C VIRUS 
 
4.1   HCV biology 
HCV is an enveloped virus with a positive sense RNA genome in the 
Hepacivirus genus of the Flaviviridae family. Each virus particle is 
approximately 55-65 nm in size [Kaito et al., 1994; Shimizu et al., 1996]. 
Electron microscopy of the virus has been hampered by the lack of a cell 
culture system that produces a sufficient amount of virus for visualization. 
However, recent work using the JFH-1 cell culture system has allowed for 
further characterization of the virus [Wakita et al., 2005]. By examining 
other viruses of the Flaviviridae family, it is believed that HCV has an 
icosahedral arrangement in which the structural glycoproteins E1 and E2 are 
embedded into a bi-layer lipid envelope derived from the host cells (figure 
12). The core protein forms the nucleocapsid of the virus that encloses the 
RNA genome [Ishida et al., 2001]. There are three forms of the virus 
present in the serum of infected individuals including free virions, 
immunoglobulin associated virions and virions associated with very-low-
density and low-density lipoproteins [Bradley et al., 1991; Thomssen et al., 
1993]. 
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Figure 12. HCV structure (adapted from Perkins JA, 2001) 
 
 
4.2 Genome Structure 
Hepatitis C virus contains a positive sense, single stranded RNA 
genome of approximately 9.5 kb. The genome consists of a single open 
reading frame flanked by 5’ and 3’ untranslated  regions (UTR) which are 
important for replication of the genome (figure 13). 
The highly conserved 5’ UTR is 341 nucleotides long and contains 
the internal ribosome entry site consisting of four major RNA domains with 
extensive secondary structure. The entire 5’ UTR is believed to be important 
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for IRES activity and HCV translation [Beales et al., 2001; Jubin et al., 
2000; Lukavsky et al., 2000]. The 3’ UTR is potentially important in 
initiating viral replication. It consists of a poly (U)/polypyrimidine tract, a 
variable 40 nucleotide sequence, and a highly conserved 98 nucleotide 
sequence with stable secondary structure [Tanaka et al., 1996; Kolykhalov 
et al., 1996]. 
 
 
 
Figure 13. HCV genome structure 
 
4.3 HCV Genotypes and Subtypes 
HCV strains are to date categorized into at least six major genotypes 
based on nucleic acid sequence. Genotypes are approximately 65% identical 
across the whole HCV genome. Within each genotype, subtypes are also 
evident with approximately 80% nucleic acid similarity [Simmonds et al., 
1994]. The different genotypes and subtypes have different geographical 
distributions and prevalence, with genotype 1 being the most prevalent 
genotype in North America and Europe while genotype 4 is most common 
in Egypt and North Africa and genotypes 5 and 6 are most common in 
South Africa and Hong Kong. Genotypes 2 and 3 are common in North 
America, Europe and Japan, but to a lesser extent than genotype 1. A high 
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number of subtypes are evident in Africa and Southeast Asia, suggesting 
that this region may be the original source of HCV as fewer subtypes are 
evident in Europe and North America [Smith and Simmonds, 1997] (figure 
14). Currently, genotyping of the virus in an infected individual is 
accomplished by DNA hybridization, restriction length fragment 
polymorphism, direct nucleotide sequencing using polymerase chain 
reaction, and serologic genotyping. Many of the current methods, excluding 
direct nucleotide sequencing, cannot discriminate between viral subtypes. 
It has become very clear that the HCV genotype is clinically 
relevant. In acute infection, the rate of progression to chronic infection has 
been related to genotype, with an increased number of genotype 1 infected 
individuals progressing to chronicity in comparison with other genotypes 
[Amoroso et al., 1998]. Perhaps more importantly, treatment response rates 
to combination therapy are directly correlated with HCV genotype. 
Genotype 1 or 4 infected individuals will only respond to treatment 
approximately 50-60% of the time, and only with a longer course of therapy 
than genotype 2 and 3 infected individuals who are able to clear the virus in 
approximately 70 to 80% of cases with a shorter treatment duration. The 
reason for this dramatic difference between genotypes is largely unknown, 
but may be related to an interferon sensitivitydetermining region in the 
NS5a protein [Enomoto et al., 1995; El-Shamy et al., 2008; Torres-Puente 
et al., 2008]. Interestingly, HCV genotype has also been correlated with the 
development of steatosis in HCV infected individuals. Several studies have 
shown that a substantially increased number of HCV genotype 3a infected 
patients have steatosis, even in the absence of contributing factors such as 
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obesity, diabetes and alcoholism. Furthermore, steatosis is abolished upon 
successful treatment and clearance of the virus, suggesting that HCV 
genotype 3a may play a direct role in altering hepatic lipid metabolism that 
is not as evident with other genotypes. Within each HCV infected 
individual, many different sequences of the virus exist which are 90-99% 
identical at the nucleotide level and are members of the same infecting 
genotype. These populations of virus, called quasispecies, are generated by 
the errorprone nature of the HCV RNA-dependent RNA polymerase during 
genomic replication.  
These quasispecies populations exists in high numbers during acute 
infection; as infection progresses, the number of dominant quasispecies 
populations decreases with the major quasispecies strain changing 
intermittently. The role of these quasispecies populations is two fold. 
Firstly, high mutation rates can result in the development of new viral 
strains that have increased viral fitness over the parent strain. Secondly, 
viral quasispecies likely serve as a mechanism for immune evasion and viral 
persistence. As the immune system mounts an antibody response against a 
particular viral epitope, the virus quickly mutates and the dominant viral 
population changes to one that the immune system no longer recognizes. In 
a similar fashion, the virus can also quickly generate mutants that are 
resistant to antiviral drugs. The high mutability of the HCV virus poses 
several challenges to the development of an effective vaccine or antiviral 
drug. 
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4.4   HCV proteins 
The HCV genome is translated into a polyprotein that is 
subsequently cleaved, by host peptidase and viral protease, into 
approximately 10 proteins in the sequence Core-E1-E2-p7-NS2-NS3-NS4a-
NS4b-NS5a-NS5B. The Core, E1, E2 and p7 proteins are considered 
structural proteins of the virus while NS2, NS3, NS4a, NS4b, NS5a and 
NS5B are non-structural proteins (figure 15).  
 
4.4.1 Structural proteins 
The core protein is cleaved from the polyprotein via host signal 
peptidase to form a 191 amino acid immature form of the protein. The core 
protein is then cleaved between amino acids 173 to 179 by host Signal 
Peptide Peptidase (SPP) to form the mature protein [Okamoto et al., 2004]. 
The core protein is a dimeric alpha-helical protein that can bind RNA and 
consists of two major domains. The D1 domain is primarily hydrophilic and 
is located in the N-terminus while the D2 domain is primarily hydrophobic 
and located in the C-terminus. D2 assists in the folding of the protein as well 
as membrane and lipid droplet association [Boulant et al., 2005; Santolini et 
al., 1994]. The core protein is localized on the endoplasmic reticulum and 
on the surface of lipid droplets in infected cells. Some studies have also 
shown a small amount of core protein in the nucleus and on mitochondria, 
but this localization has not been observed in infected cells [McLauchlan, 
2000; Hope et al., 2002; Suzuki et al., 2005; Rouille et al., 2006]. 
Localization of core with lipid droplets is also mediated by proteolytic 
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cleavage by SPP [McLauchlan et al., 2002]. Mature core proteins form the 
nucleocapsid of the virus. However, many studies have shown alternative 
roles for the core protein in the pathogenesis of HCV including apoptosis, 
insulin resistance, cell cycle, and lipid metabolism. Interestingly, the core 
protein-encoding region also contains a +1 alternative reading frame that 
results in translation of the ARF (alternative reading frame) protein. The F 
protein does not contain an AUG start codon, so translation of this protein is 
a random event. No known function of the F protein is currently known. 
Although antibodies against it are present in HCV infected individuals, it is 
not required for viral replication [Branch et al., 2005]. 
The E1 and E2 proteins of HCV are envelope glycoproteins that are 
essential for virus entry and form heterodimers on the viral envelope. The 
E2 protein contains a hypervariable region that mutates frequently to allow 
for the development of immune escape variants [Forns et al., 2000; Callens 
et al., 2005]. 
The p7 protein has recently been found to have ion-channel activity 
and it is essential for virus infectivity. As such, new research has been 
directed toward developing antiviral compounds to block the function of 
this protein [Saint et al., 2009]. 
 
4.4.2  Non-structural proteins 
The NS2 protein is a hydrophobic protease that cleaves the HCV 
polyprotein between NS2 and NS3 and it may function as a novel cysteine 
protease. Efficient cleavage of NS2/3 is required for HCV replication, but 
the presence of NS2 is not required for genome replication. Following 
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cleavage, NS2 is localized in the ER membrane. Besides its protease 
activity, NS2 appears to be involved in apoptosis, cell proliferation, innate 
immunity and lipid metabolism [Dumoulin et al., 2003; Erdtmann et al., 
2003; Yang et al., 2006; Oem et al., 2007]. 
The NS3 protein is a protease and RNA helicase. The Protease 
activity of NS3 is mediated by the NS4a protein and both proteins are 
localized on the ER. The NS3/4a protease complex cleaves the HCV 
polyprotein downstream of NS3 and this action is essential for formation of 
the viral replication complex [Lindenbach et al., 2005] (figure 15). The 
NS3/4a is able to inhibit the host innate immune response via disrupting the 
RNA helicase retinoic acid-inducible gene-I (RIG-I) pathway by cleaving 
Cardif, an adaptor protein of interferon regulatory factor-3 [Foy et al., 
2003]. The function of the NS3/4a helicase activity is still unknown. 
The NS4b protein is present on the ER membrane and induces 
intracellular membrane changes that may be involved in the formation of the 
replication complex membranous webs [Hugle et al., 2001; Egger et al., 
2002]. It also contains a nucleotide binding motif that hydrolyzes GTP 
[Einav et al., 2004]. NS4b is thought to play a major role in viral 
replication, assembly and release as well as lipid metabolism [Jones et al., 
2009; Park et al., 2009]. 
The NS5a is also an ER-associated protein that is particularly multi-
functional. It can bind to HCV RNA and it is essential for viral replication 
[Huang et al., 2005]. It can be hyperphosphorylated in order to inhibit viral 
replication [Evans et al., 2004]. NS5a is also able to decrease the immune 
response via inhibition of interferon-induced double stranded RNA 
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activated protein kinase PKR [Gale et al., 1998]. NS5a may also play a role 
in mediating lipid metabolism as it interacts with core proteins on the 
surface of lipid droplets and it also interacts with apolipoproteins [Shi et al., 
2002]. 
The NS5B is an RNA dependent RNA polymerase that synthesizes 
RNA using an RNA template. It is also localized on the ER membrane and 
it is essential for viral replication. As such, it is a prime target for the 
development of antiviral compounds [Lohmann et al., 2000]. 
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4.5 HCV life cycle 
4.5.1 Receptors and entry 
The entry of HCV into a naïve host cell appears to be a complicated, 
multi-step process involving several different host receptors. The initial 
entry steps have only been recently characterized thanks to the newly 
developed infectious cell culture system, and many details are still to be 
discovered. Heparin, a glycosaminoglycan, has been long suspected to play 
a role in viral entry with several studies showing inhibition of viral 
attachment in the presence of heparinase, an enzyme that disrupts heparin 
[Koutsoudakis et al., 2006; Barth et al., 2003; Barth et al., 2006]. Low-
density lipoprotein receptor (LDLR) is very likely a critical component of 
viral attachment. HCV in the serum of infected patients is bound to low 
density and very low-density lipoproteins. Adsorption of HCV from the 
serum of infected patients can be inhibited through the use of antibodies 
against LDLR suggesting that the association of HCV with lipoproteins is 
an important step in attachment of the virus [Thomssen et al., 1992; Andre 
et al., 2002; Huang et al., 2007a; Monazahian et al., 1999; Molina et al., 
2007]. CD81, a cell surface protein in the tetraspanin family, is considered 
one of the major players in HCV attachment. Antibodies against CD81 
effectively inhibit HCV infectivity in different models. In addition, HepG2 
and HH29 hepatoma cells, which are not normally permissive to HCV 
infection, can be infected following ectopic expression of CD81 [Cormier et 
al., 2004; Wakita et al., 2005]. However, expression of CD81 in other non-
permissive cell lines does not allow HCV infection to occur, suggesting that 
other host cell factors may be involved in the attachment and entry process 
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[Bartosch et al., 2003]. Scavenger receptor class B type I (SR-BI) is another 
cell surface protein that may be involved in viral attachment and entry. SR-
BI is a receptor for lipoproteins and it can also change the lipid composition 
of membranes. Blocking of SR-BI with antibodies can prevent virus entry. It 
is still unclear whether SR-BI is interacting directly with the virus proteins 
or if it is interacting with virus associated lipoproteins to mediate virus entry 
as both mechanisms have been observed [Bartosch et al., 2003; Catanese et 
al., 2007; Acton et al., 1996; Maillard et al., 2006; Huang et al., 2003]. 
Recently, two tight junction cell proteins Claudin-1 and Occludin have been 
shown to be involved in HCV entry. Claudin-1 can be ectopically expressed 
in non-permissive, non-hepatic 293T cells and allow HCV infection to 
occur. Knock-down of Claudin-1 in permissive Huh7 cells can reduce HCV 
infectivity. It has also been found that Claudin-1 and Occludin are involved 
in late entry of the virus into the cell, which likely occurs through 
interaction with the tight junctions [Evans et al., 2007]. The use of the tight 
junctions by HCV may also allow for cell to cell spread of the virus [Timpe 
et al., 2008]. It has been shown that HCV entry is mediated by endocytosis 
in a pH-dependant manner. In addition, knock-down of clathrin, a critical 
component of the endocytotic vesicles, prevents HCV infection [Meertens et 
al., 2006; Blanchard et al., 2006]. Fusion of the virus envelope with the 
endosome membrane is not well characterized and both E1 and E2 are likely 
involved in the process [Lavillette et al., 2007]. 
 
 
 
102 
 
4.5.2 Replication, assembly and release 
HCV replication occurs in a membrane associated replication 
complex that contains several viral and host proteins and replicating RNA. 
The positive strand of the virus RNA genome is made into a negative strand 
that is then used to make more positive strand copies for packaging. The 
NS5B protein is the major player in the synthesis of both the positive and 
negative strands. The HCV replication complex appears to contain a 
membrane alteration called a membranous web that can be observed by 
electron microscopy in infected cells in vitro and in vivo, as well as in cells 
expressing the NS4b protein alone. The source of the membranous web is 
likely the ER as most of the HCV proteins are associated with the ER upon 
translation [Shi et al., 2003; Gosert et al., 2003]. It is also possible that viral 
replication is occurring on lipid rafts that contain large amounts of 
cholesterol and sphingolipids. Inhibitors of sphingolipid synthesis can 
prevent HCV replication and both non-structural proteins and replicating 
RNA are found on lipid rafts [Sakamoto et al., 2005; Matto et al., 2004; 
Aizaki et al., 2004; Shi et al., 2003]. Recently, it has been determined that 
lipid droplets play an important role in virus assembly. Core protein 
localizes around lipid droplets where it recruits non-structural proteins and 
replication complexes. Inhibiting lipid droplet localization of core protein 
decreased the production of infectious virus particles [Miyanari et al., 
2007]. There are also many different host cell proteins with putative roles in 
HCV replication. For example, vesicle-associated membrane proteins A and 
B (VAP-A and VAP-B) localize in the ER and bind both NS5a and NS5B 
and are essential for viral replication [Hamamoto et al., 2005]. Cyclophilin 
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B, a peptidyl-prolyl cis-trans isomerase, binds to NS5B and enhances its 
RNA binding activity [Watashi et al., 2005]. Similarly, p68, and RNA 
helicase, binds NS5B and moves into the cytoplasm from the nucleus to 
assist in viral replication [Goh et al., 2004]. Very little is known about HCV 
assembly and release. There are several different forms of the virus found in 
infected serum, including free mature virions, virions bound to low-density 
and very low-density lipoproteins, virions bound to immunoglobulins and 
non-enveloped nucleocapsids. It is believed that viral RNA can interact with 
the core protein, which then oligomerizes to form the nucleocapsid around 
the viral RNA [Tanaka et al., 2000]. The envelope of the virus is then 
obtained through core interaction with E1 glycoprotein on the ER 
membrane, from which budding occurs [Ezelle et al., 2002; Murakami et 
al., 2006]. From this point it is thought that the virus is released from the 
cell after transit through the Golgi apparatus and the secretory pathway 
[Serafino et al., 2003]. 
 
 
4.5.3 Virus-like particles 
In the serum of HCV infected individuals, several different forms of 
HCV can be found that differ in both size and density. Currently very little 
is known about HCV assembly and how these different types of HCV 
particles are formed and secreted. HCV RNA can be found in infected 
serum at a density between 1.03 and 1.25 g/ml [Thomssen et al., 1992; 
Thomssen et al., 1993]. Interestingly, the lower density particles appear to 
be more infectious than the higher density particles when tested in 
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chimpanzees [Bradley et al., 1991; Hijikata et al., 1993]. The low-density 
particles contain high amounts of triglycerides, as well as HCV RNA, core 
protein and apolipoproteins B and E (ApoB and ApoE). Triglycerides along 
with ApoB and ApoE are the major components of very-low density 
lipoproteins (VLDL) and low-density lipoproteins (LDL) which are 
particles packaged in the ER of hepatocytes to be secreted into the 
bloodstream and transport their triglyceride load to adipocytes for storage 
[Rustaeus et al., 1999]. During HCV infection, assembled virus particles are 
hypothesized to use this pathway to acquire ApoB, ApoE and triglycerides 
prior to secretion from the cells. Virus particles that do not obtain the 
necessary triglycerides and apolipoproteins are not secreted from the cell 
and undergo degradation. Exploitation of the VLDL assembly pathway by 
HCV ultimately decreases lipid export from the cells and could be an 
important factor in the development of steatosis in infected patients. The 
addition of apolipoproteins and triglyceride to the virus particle could also 
be advantageous to the virus as it could be providing a mechanism of 
immune escape by hiding viral epitopes and also by increasing the number 
of potential receptors (ie. CD81, LDLR and SR-BI) for attachment 
[Gastaminza et al., 2008; Huang et al., 2007a; Nielsen et al., 2006; Andre et 
al., 2002; Perlemuter et al., 2002]. 
Another fraction of the HCV population in infected serum appears to 
be nonenveloped. These particles have a higher density and vary in size. 
The core protein is displayed on the surface of these particles and antibodies 
against core protein are a hallmark of HCV infection. Currently it is 
unknown whether these nonenveloped particles are infectious or what role 
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they play in the course of HCV infection and pathogenesis [Maillard et al., 
2001]. 
 
 
4.6 HCV Clinical Characteristics 
4.6.1 Acute viral infection 
Upon infection with HCV, most patients enter an acute phase that is 
largely asymptomatic. Most of the infected individuals (~80%) will progress 
to chronic HCV infection while the other 20% will clear the virus within the 
first 3 months after infection. 
The asymptomatic nature of the acute stage of infection results in 
difficulty in diagnosing and reporting HCV infection, as well as difficulty in 
studying the aspects of the immune response that allow for viral clearance 
during this time. The greatest risk of infection with HCV is through 
intravenous drug use (IDU), unprotected sex, exposure during medical 
procedures, vertical transmission from mother to child, or needle injury in 
health care professionals. Blood transfusion prior to 1992 is also an 
important risk factor [Centers for Disease Control and Prevention, 2007]. 
The HCV RNA can be detected in the serum approximately 1-3 
weeks after exposure. Symptoms include fatigue, jaundice, dyspepsia, and 
abdominal pain but are generally not specific or severe enough to warrant 
consultation of a doctor. Elevated alanine aminotransferase (ALT) levels 
can be detected 4-12 weeks after exposure and are the first indication of 
liver injury [Santantonio et al., 2003]. Serum HCV RNA and anti-HCV 
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antibody seroconversion is generally used to detect HCV infection 
[Pawlotsky, 2002].  
Host and viral factors appear to contribute to viral clearance in acute 
infection including genotype of the virus, HIV co-infection, gender, race, 
age and HLA [Lehmann et al., 2004]. A strong cellular immune response is 
also thought to increase viral clearance, and symptomatic infection appears 
to correlate with viral clearance [Gruner et al., 2000; Thimme et al., 2001]. 
Patients who spontaneously clear the virus need to be monitored as disease 
relapse may occur up to 6 months after clearance [Gerlach et al., 1999]. 
 
4.6.2 Chronic viral infection 
Infection with HCV is one of the leading causes of liver disease 
worldwide. As previously discussed, a small proportion of people are able to 
clear the virus following an acute infection but the majority progress to a 
chronically infected state. Chronic infection can persist for many years 
without causing the death of the patient. However, most cases eventually 
lead to the development of hepatitis, fibrosis, steatosis and cirrhosis with the 
eventual need for a liver transplant if left untreated. A small number of 
HCV infected individuals will also develop hepatocellular carcinoma. Host 
factors such as age, obesity, alcohol use, gender, race and co-infection with 
HIV or HBV can increase the rate of progression of liver damage [Soto et 
al., 1997; Pontisso et al., 1998; Corrao and Arico, 1998]. Genotype does not 
appear to play a role in disease progression [Silini et al., 1996]. However, 
the presence of non-alcoholic steatohepatitis can increase progression of 
disease, and infection with genotype 3a is associated with a higher 
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prevalence of steatosis [Mihm et al., 1997; Adinolfi et al., 2001]. In general, 
the rate of progression to cirrhosis is unpredictable in chronic HCV 
infection [Ascione et al., 2007]. 
 
 
4.6.3 Associated clinical pathology 
4.6.3a Hepatitis, steatosis, fibrosis and cirrhosis 
The HCV is not generally considered to be a cytopathic virus. 
Damage to the liver is thought to be primarily the result of 
immunopathogenic mechanisms. However, HCV has been associated with 
direct cytopathic effects on the liver such as apoptosis, stellate cell 
activation, the development of steatosis and insulin resistance. Damage to 
the liver is clinically observed by increased ALT levels. In the case of HCV, 
liver biopsies are often taken to assess the stage of liver disease. Hepatitis of 
the liver occurs following an infiltration of inflammatory cells into the liver 
and damage of the hepatocytes leads to steatosis and fibrosis. Steatosis of 
the liver is the accumulation of lipid within hepatocytes that can eventually 
lead to the development of fibrosis. Fibrosis of the liver is characterized by 
the accumulation of extracellular matrix proteins, like collagen, that are 
produced by different liver cell types following damage. 
Liver fibrosis can be reversed [Bataller and Brenner, 2005]. 
Cirrhosis is the final stage of liver disease in which liver tissue is replaced 
by scar tissue and nodules that decrease liver function. Cirrhosis is 
irreversible and patients in the advanced stages of liver cirrhosis will need a 
liver transplant [Mengshol et al., 2007].  
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4.6.3b Lymphoproliferative disorders 
One of the best characterized extra-hepatic disorders associated with 
HCV infection is mixed cryoglobulinemia (MC). MC is caused by the 
development of cryoglobulins consisting of polyclonal IgG and monoclonal 
IgM or polyclonal IgM with rheumatoid factor that precipitate in the blood 
at less than 37°C [Zignego 1997]. Symptoms include weakness, arthralgias, 
and palpable purpura in the lower extremities and complications can include 
kidney damage and possibly liver damage [Ferri 1992; Kayali 2002; 
Saadoun 2006]. Approximately 5-10% of HCV patients exhibit MC [Lunel 
1994]. Successful treatment of the HCV infection results in eradication of 
MC in most patients [Zignego 2007b]. HCV is also associated with 
malignant lymphomas that may be related to MC. B-cell derived Non-
Hodgkin’s Lymphoma is the most common lymphoma associated with HCV 
infection [De Vita 1997]. 
 
4.6.3c Hepatocellular carcinoma 
Infection with HCV is a major risk factor for the development of 
hepatocellular carcinoma (HCC). The mechanism by which HCV causes 
HCC is unknown but several studies have indicated a role for the core 
protein, including the induction of oxidative stress and steatosis. Cellular 
signaling pathways are also changed by the core protein, as previously 
discussed. The development of liver fibrosis and cirrhosis also increases the 
risk for HCC. Approximately 1-3% of HCV patients will develop HCC after 
30 years of chronic infection [Hassan et al., 2002]. Age, alcohol 
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consumption, obesity, diabetes, genotype and co-infection with HBV or 
HIV can all increase the risk of developing HCC in HCV infected patients 
[El-Serag, 2002]. 
 
4.7 HCV test for diagnosis and monitoring 
Diagnosis of chronic HCV infection is based on the presence of both 
anti-HCV antibodies, detected by enzyme immunoassays (EIA), and HCV 
RNA, detected by molecular assays. HCV RNA testing is essential for the 
management of HCV therapy [Chevaliez S et al., 2008]. As previously 
described for HBV (session 2.2.1) the most recent assays are based on the 
use of real-time polymerase chain reaction (PCR). This method can detect 
very little amounts of HCV RNA (down to 10 international units IU/ml) and 
accurately quantify HCV RNA levels up to approximately 10
7
 IU/ml. Their 
dynamic range of quantification adequately covers the clinical needs for 
diagnosis and monitoring [Vermehren J et al., 2008, Chevaliez S et al., 
2009, Fytili P et al., 2007].  
HCV genotype and subtype can be determined via various methods, 
including direct sequence analysis, reverse hybridization (INNO-LiPA), and 
genotype-specific real-time PCR [Chevaliez S et al., 2008] with the first two 
more commonly used in laboratory for routinary use. However, these assays 
targeting the 5’ noncoding region (5’ UTR) of the HCV genome, fail to 
differentiate HCV subtypes 1a and 1b. In particular, Trugene HCV 
Genotyping Kit (Direct sequencing based method) and INNO-LiPA HCV 
1.0, failed to correctly identify HCV subtype 1a in 22.8% and 29.5% of 
cases, and HCV subtype 1b in 9.5% and 8.7% of cases, respectively. The 
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INNO-LiPA HCV has been recently improved adding, in the version 2.0, 
the core-encoded oligonucleotide probes to better discriminate between 
HCV subtypes 1a and 1b. With INNO-LiPA HCV 2.0, subtype 
identification was corrected in 97.5% and 96.2% of subtype 1a and 1b 
respectively [Chevaliez S et al., 2009]. 
Although genotype information is enough for SOC management, the 
correct subtype identification is becoming more and more important with 
the introduction of the DAAs since subtype, specific, single nucleotide 
polymorphisms can affect the development of drug resistant variant as in the 
case of subtype 1a and 1b [Kieffer TL, et al. 2007].  
Therefore, sequencing or reverse hybridization-based methods targeting 
segments other than the 5’ UTR region are going to be required in the very 
next future [Chevaliez S et al., 2009]. 
 
4.8 HCV Treatment 
Until recently, standard of care (SOC) for chronic HCV infections 
has been limited to combination of pegylated interferon-α 2a/2b plus 
ribavirin. Whilst SOC is generally successful in eradicating the virus in 80% 
of genotype 2 and 3 patients, the efficacy of this regimen is lower in case of 
infection with HCV genotype 1 and 4 (eradicating the 42% and 69% 
respectively). Moreover, SOC is associated with significant Flu-like 
symptoms following each injection (fever, chills, headache, muscle aches 
and pains, malaise). These symptoms vary from mild to severe and occur in 
up to half of all patients. For this reasons, Direct Acting Antiviral (DAAs), 
new classes of anti-HCV agents, have been developed in the last years. 
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Many of them are currently going through clinical trials while two, 
Telaprevir and Boceprevir, have been approved by the Food and Drug 
Administration (FDA) in April and May 2011 respectively, to be used in 
combination with SOC. 
 
4.8.1 Ribavirin plus interferon combination therapy: mechanism of 
action. 
As previously described in the HBV session 2.3.1, interferons are 
cellular proteins able to induce an antiviral state in their target cells, as well 
as cytokine secretion, recruitment of immune cells, and cell differentiation. 
Concerning the HCV infection, their metabolism and mechanisms were 
recently reviewed [Chevaliez S et al., 2009]. 
Immediately after injection, IFN-α binds to receptors present on various 
cells including hepatocytes, triggering a sequence of intracellular reactions 
that activate IFN-inducible genes (ISGs). The products of these genes are 
responsible for the IFN-α-mediated antiviral effects, achieved via two 
mechanisms. One, indicated as the first phase, is the induction of a 
nonvirus-specific replication inhibition in infected cells. The IFN-α was 
found to directly inhibit HCV replication in vitro in the subgenomic replicon 
(a synthetic replication system using HCV nonstructural proteins in various 
cell lines) [Kim CS et al., 2007]. The second mechanism, second phase of 
response, involves immunomodulatory effects that enhance the host’s 
specific antiviral immune response, thus clearing the infected cells 
[Chevaliez S et al., 2009] (figure 16). The induction of the antiviral state 
could potentially extend to noninfected cells, thus reducing the chance that 
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they will become infected. Upon the interaction of IFN-α with its receptor, 
many complex effects are generated, including the induction of major 
histocompatibility complex class I (MHC I) antigen expression, activation 
of macrophages, natural killer cells and T lymphocytes, production of 
primarily T-helper 1 (Th1) cells, and decreased production of T helper-2 
(Th2) cells. PEG-IFN-α also interacts with cytokines such as CCL 
chemokines and tumor necrosis factor (TNF)-α. Soluble TNF-α receptors 
(sTNF-R), which are released by activated neutrophils, mononuclear blood 
cells, and fibroblasts [Porteu F et al 1991, Lien E et al., 1995] in response to 
mediators, such as interferon and TNF- α itself [Lien E et al., 1995, Lantz M 
et al., 1990, Joyce DA et al., 1994, Tilg H et al., 1995], retain their ability to 
bind circulating TNF- α and are important in regulating its activity. These 
sTNF-R may contribute to the anti-inflammatory action of IFN-α. All of 
these effects suggest that IFN-α simply accelerates the host immune 
response, though no studies have clearly proven it. HCV genotypes 1 and 4 
are intrinsically more resistant to IFN-α than genotypes 2 and 3. 
Consequently, the clearance of infected cells in patient who are interferon 
responders occurs much slower in genotypes 1 and 4, as compared to 2 and 
3 [Neumann AU et al., 2002, Pawlotsky JM et al., 2002]. The mechanisms 
underlying these differences are yet to be defined. The combination of IFN 
induced proteins and pathways responsible for inducing an antiviral state 
has not been completely mapped out, though various effectors have been 
proposed including the 2’–5’ oligoadenylate synthetase (2’–5’ OAS) 
system, Mx proteins, double-strand-RNA-dependent protein kinase (PKR), 
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as well as other, less well-characterized/unknown IFN-induced intracellular 
pathways [Chevaliez S et al., 2009].  
 
Figure 16. Phases of antiviral treatment of chronic hepatitis C. Source:  
Ferenci P. Nature Reviews Gastroenterology & Hepatology 7, 191-193 
(April 2010). 
 
 
Ribavirin is a synthetic guanosine analog that undergoes intracellular 
phosphorylation, with the ultimate product, ribavirin triphosphate, being 
responsible for ribavirin’s effects. In vivo, ribavirin has a moderate (<0.5 
log HCV RNA reduction) and transient inhibitory effect of only 2-3 days 
duration on HCV replication, and this is only seen in about 50% of patients 
[Pawlotsky JM et al., 2004]. These effects are consistent with those seen in 
in vitro studies, and the modesty of the effect could be related to the drug’s 
weak inhibitory action on the RNAdependent RNA polymerase (RdRp) 
[Lau JYN et al., 2002]. Fortunately, this effect is too weak and transient to 
account for selecting viral resistance to ribavirin. Despite its apparently 
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weak antiviral effects, ribavirin remains essential to HCV treatment, as it 
appears to accelerate the clearance of infected cells through unknown 
mechanisms and to prevent viral breakthrough during treatment, and 
relapses following treatment, in patients on IFN-α [Bronowicky JP et al., 
200633]. Studies have suggested that ribavirin is an RNA mutagen, causing 
loss of viral “fitness” via lethal nucleoside accumulation during replication 
[Contreras AM et al., 2002], though no excessive mutagenesis was noted 
during ribavirin therapy in HCV infection [Chevaliez S et al., 2007, 
Lutchman G et al., 2007]. Ribavirin, much like IFN-α, has 
immunomodulatory effects, including preferentially driving the immune 
system to produce more Th1 cells relative to Th2 [Fanf SH et al., 2000]. 
Some reports have suggested that ribavirin can also amplify the intracellular 
IFN-α responses, via unknown mechanisms [Feld JJ et al., 2007]. According 
to Tang et al., IFN-α attachment to interferon alpha receptors (IFNAR) 
[Tang KH et al., 2005] and the very rapid activation of Interferon 
Stimulated Genes (ISG) after interferon alpha administration [Feld JJ et al., 
2005] could explain the effect of IFN-α as a potent immunostimulant of an 
innate response in the first few hours and an adaptive response after the first 
four weeks. [Ji X et al., 2003]. The degree of the ISG-induced innate 
response may result in a rapid decline of HCV replication (as measured by a 
decrease of HCV-RNA levels), which, if significant enough, causes very 
distinct CD4 and CD8 responses (shifting the immune response from innate 
to adaptive). Clinically, this phenomenon defines a group of patients known 
as rapid responders (HCV RNA serologic negativity achieved by week 4 of 
treatment) and differentiates them from patients with a less vigorous early 
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reduction in viral load, known as slow responders. Sustained virologic 
response (SVR) is achieved when no virus is detected in the blood for six 
months after finishing treatment and prognosticates a 99% chance of 
indefinitely eradicating HCV, which for many experts is equivalent to 
curing HCV. Several events need to work in concert in order to achieve 
SVR, including (i) successfully achieve a rapid phase 1 effect by turning off 
viral replication, (ii) effectively suppress the viral load throughout 
treatment, and (iii) induce a solid and persistent Phase 2 effect [Araujo ES et 
al., 2007] (figure 16). It has been hypothesized that phase 2 is driven by the 
host’s adaptive immune response in the context of sustained inhibition of 
virus production, while restoration of the innate immune response by viral 
inhibition leads to clearance of residual HCV-infected cells [Neumann AU 
et al., 1998]. 
 
4.8.2 Direct Acting Anti-viral drugs 
The five steps in HCV replication that are potential targets for direct-
acting antivirals include initial binding of HCV to hepatocyte surface 
receptors (via LDLR and CD81), translation and polyprotein processing (via 
the HCV protease complex), RNA replication (via the HCV RNA-
dependent polymerase complex), virion assembly and maturation, followed 
by release from the hepatocyte. To date, the most successful approaches 
have been targeting the HCV protease (via inhibition of NS3A4 protease) 
and the HCV polymerase complex (via inhibition of NS5A, NSAb and 
indirectly through NS3A4). The in vitro replicon and transgenic models for 
HCV replication and the application of rapid screening techniques for small 
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molecules have triggered an explosion in drug development. During the last 
years, about a hundred of protease and polymerase inhibitors have entered 
clinical development, of which several have halted because of toxicity 
(BILN2061, NM283, HCV796, R1626) and many more have been 
abandoned because of preclinical toxicity signals or lack of clinical efficacy 
(table 6). 
 
Table 6. Direct Acting Antiviral for HCV therapy. 
Drug name  Company Target  Target Active site  Phase 
NS3-4A protease Inhibitors 
    
Ciluprevir (BILN 2061) 
Boehringer 
Ingelheim  Active site  macrocyclic Stopped 
Telaprevir (VX-950)  Vertex  Janssen  Active site  linear Approved 
Boceprevir (SCH503034)  Merck (S-P)  Active site  linear Approved 
Simeprevir (TMC435350)  Janssen Medivir  Active site  macrocyclic III 
Danoprevir (R7227)  Roche InterMune  Active site  macrocyclic II 
Vaniprevir (MK-7009)  Merck  Active site  macrocyclic Halted II 
MK-5172  Merck  Active site  macrocyclic II 
BI201335 
 Boehringer 
Ingelheim  Active site  linear III 
Narlaprevir (SCH900518)  Schering-Plough  Active site  linear Halted 
Asunaprevir (BMS-650032) 
 Bristol-Myers 
Squibb  Active site 
 
II 
PHX1766  Phenomix  Active site 
 
I 
GS-9256  Gilead  Active site 
 
II 
GS-9451  Gilead  Active site 
 
I 
ABT450  Abbott  Active site 
 
II 
IDX320  Idenix  Active site 
 
II 
ACH-1625  Achillion  Active site macrocyclic? II 
Nucleoside analog NS5B polymerase 
Inhibitors 
    
Valopicitabine (NM283)  Idenix Novartis  Active site 
 
Stopped 
Mericitabine (R7128)  Roche Pharmasset  Active site 
 
II 
R1626  Roche Active site 
  
Stopped 
PSI-7977  Pharmasset  Active site 
 
II 
PSI-938  Pharmasset  Active site 
 
II 
IDX184  Idenix  Active site 
 
II 
Non-nucleoside NS5B polymerase 
Inhibitors (NNI) 
    
BILB 1941 
Boehringer 
Ingelheim  NNI site 1  thumb 1 Stopped 
BI207127 
 Boehringer 
Ingelheim  NNI site 2  thumb 1 II 
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Drug name  Company Target  Target Active site  Phase 
MK-3281  Merck  NNI site 1  thumb 1 II 
TMC647055  Janssen  NNI site 1  thumb 1 
 
Filibuvir (PF-00868554)  Pfizer  NNI site 2  thumb 2 II 
VCH759  ViroChem Pharma  NNI site 2  thumb 2 II 
VCH916  ViroChem Pharma  NNI site 2  thumb 2 II 
VCH222  ViroChem Pharma  NNI site 2  thumb 2 II 
ANA598  Anadys  NNI site 3  palm 1 II 
ABT-072  Abbott  NNI site 3  palm 1 II 
ABT-333  Abbott  NNI site 3  palm 1 II 
HCV-796  ViroPharma Wyeth  NNI site 4  palm 2 Stopped 
GS-9190  Gilead  NNI site 4  palm 2 II 
IDX375  Idenix  NNI site 4  palm 2 II 
NS5A Inhibitor 
    
Daclatasvir (BMS-790052) 
Bristol-Myers 
Squibb 
NS5A 
domain 1  Inhibitor II 
BMS-824393 
 Bristol-Myers 
Squibb 
 NS5A 
protein 
 
I 
PPI-461 
 Presidio 
Pharmaceuticals 
 NS5A 
protein 
 
I 
GS-5885  Gilead 
 NS5A 
protein 
 
I 
Indirect Inhibitors unknown 
mechanism of action 
    
Alisporivir (Debio-025)  Debiopharm  Cyclophilin  Inhibitor III 
NIM811  Novartis  Cyclophilin  Inhibitor I 
SCY-635  Scynexis  Cyclophilin  Inhibitor II 
Miravirsen  Santaris  miRNA122 
 antisense 
RNA II 
      
 
4.8.2a NS3-4A protease inhibitors and main resistant patterns 
HCV NS3-4A protease inhibitors (PI) can be divided into two 
classes, the macrocyclic inhibitors and linear tetrapeptide α-ketoamide 
derivatives. In general, NS3-4A protease inhibitors have been shown to 
strongly inhibit HCV replication during monotherapy, but also may cause 
the selection of resistant mutants, which is followed by viral breakthrough. 
The additional administration of pegylated interferon and ribavirin, 
however, was shown to reduce the frequency of development of resistance. 
Future strategies aim for combination therapies with different antiviral drugs 
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to prevent the development of resistance. To date the most advanced 
compounds are telaprevir and boceprevir, both approved in 2011 for the 
treatment of chronic hepatitis C virus genotype 1 infection by the FDA, 
European Medicin Agency (EMA) and in several other countries. 
Telaprevir and boceprevir are protease inhibitors belonging to the 
class of α-ketoamid derivatives. Like other NS3-4A inhibitors, telaprevir 
and boceprevir are characterized by a remarkable antiviral activity against 
HCV genotype 1. Phase II and III clinical studies have shown that the 
addition of pegylated interferon α plus ribavirin leads to significantly higher 
SVR rates in both treatment-naïve and treatment-experienced HCV 
genotype 1 patients compared to treatment with pegylated interferon α and 
ribavirin alone [Bacon et al., 2011, Jacobson et al., 2011, Poordad et al., 
2011, Sherman et al., 2011, Zeuzem et al., 2011]. Other NS3 protease 
inhibitors are currently in various phases of development (danoprevir 
(R7227/ITMN191), vaniprevir (MK-7009), BI201335, simeprevir 
(TMC435350), narlaprevir (SCH900518), asunaprevir (BMS-650032), 
PHX1766, ACH-1625, IDX320, ABT-450, MK-5172, GS-9256, GS-9451) 
and will significantly increase treatment options for chronic hepatitis C in 
the near future, possibly with improved tolerability, broader genotypic 
activity and different resistance profiles. 
Because of the high replication rate of HCV and the poor fidelity of 
its RNAdependent RNA polymerase, numerous variants (quasispecies) are 
continuously produced during HCV replication. Among them, variants 
carrying mutations altering the conformation of the binding sites of DAA 
compounds can develop. 
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During treatment with specific antivirals, these preexisting drug-
resistant variants have a fitness advantage and can be selected to become the 
dominant viral quasispecies. Many of these resistant mutants exhibit an 
attenuated replication with the consequence that, after termination of 
exposure to specific antivirals, the wild type may displace the resistant 
variants [Sarrazin et al., 2007]. Nevertheless, HCV quasispecies resistant to 
NS3-4A protease inhibitors or non-nucleoside polymerase inhibitors can be 
detected at low levels in some patients (approx. 1%) who have never been 
treated with these specific antivirals before [Gaudieri et al., 2009]. The 
clinical relevance of these pre-existing mutants is not completely 
understood, although there is evidence that they may reduce the chance of 
achieving an SVR with DAA-based triple therapies if the patient’s 
individual sensitivity to pegylated interferon α + ribavirin is low. The NS3-
4A inhibitors resistance profile are summarize in Table 7. Although the 
resistance profiles differ significantly, R155 is an overlapping position for 
resistance development and different mutations at this position confer 
resistance to nearly all protease inhibitors currently in advanced clinical 
development [Sarrazin et al., 2010]. Importantly, many resistance mutations 
could be detected in vivo only by clonal sequencing. For example, 
mutations at four positions conferring telaprevir resistance have been 
characterized so far (V36A/M/L, T54A, R155K/M/S/T and A156S/T), but 
only A156 could be identified initially in vitro in the replicon system [Lin et 
al., 2005]. These mutations, alone or as double mutations, conferred low 
(V36A/M, T54A, R155K/T, A156S) to high (A156T/V, V36M + R155K, 
V36M + 156T) levels of resistance to telaprevir [Sarrazin et al., 2007]. It is 
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thought that the resulting amino acid changes of these mutations alter the 
confirmation of the catalytic pocket of the protease, which impedes binding 
of the protease inhibitor [Welsch et al., 2008]. 
 
4.8.2b NS5B Polymerase Inhibitors 
NS5B RNA polymerase inhibitors can be divided into two distinct 
categories: Nucleoside analog inhibitors (NIs) and Non-nucleoside analog 
Inhibitors (NNI). Among the former, valopicitabine (NM283), mericitabine 
(R7128), R1626, PSI-7977, PSI-938 or IDX184 mimic the natural substrates 
of the polymerase and are incorporated into the growing RNA chain, thus 
causing direct chain termination by tackling the active site of NS5B [Koch 
et al., 2006]. Because the active centre of NS5B is a highly conserved 
region of the HCV genome, NIs are potentially effective against different 
genotypes. Single amino acid substitutions in every position of the active 
centre may result in loss of function or in extremely impaired replicative 
fitness. Thus, there is a relatively high barrier in the development of 
resistances to NIs. 
In contrast to NIs, the heterogeneous class of non-nucleoside 
inhibitors (NNIs) achieves NS5B inhibition by binding to different allosteric 
enzyme sites, which results in conformational protein change before the 
elongation complex is formed [Beaulieu et al., 2007]. For allosteric NS5B 
inhibition high chemical affinity is required. The NS5B is structurally 
organized in a characteristic “right hand motif”, containing finger, palm and 
thumb domains, and offers at least four NNI-binding sites, a benzimidazole-
(thumb 1)-, thiophene-(thumb 2)-, benzothiadiazine-(palm 1)- and 
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benzofuran-(palm 2)-binding site [Lesburg et al., 1999] (Figure 17). 
Because of their distinct binding sites, different polymerase inhibitors can 
theoretically be used in combination or in sequence to manage the 
development of resistance that might be already there, before any treatment, 
as a consequence of the poor fidelity leading to a high rate of errors in the 
HCV RNA progenies. Indeed, numerous different HCV quasispecies are 
generated during HCV replication in a given patient. It is reasoned that due 
to the lack of proofreading of the NS5B polymerase together with the high 
replication of HCV, every possible mutation is generated each day.  
 
 
Figure 17. Structure of the HCV NS5B RNA polymerase and binding sites. 
 
4.8.2c NS5A Inhibitors and resistant mutants associated 
Daclatasvir BMS-790052 was the first NS5A inhibitor to be 
clinically evaluated. Even low doses of this drug display high antiviral 
efficacy against all HCV genotypes in vitro. Monotherapy with BMS-
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790052 led to a sharp initial decline of HCV RNA concentrations, though its 
genetic barrier to resistance is relatively low [Gao et al., 2010]. 
According to an interim analysis of a Phase IIb clinical trial in 
treatment-naïve HCV genotype 1 and 4 patients, treatment with 20 or 60 mg 
BMS-790052 once daily in combination with PEG-IFN α and ribavirin for 
24 or 28 weeks, 54% of all patients achieved an extended RVR, compared 
to 13% in the control group [Hezode et al., 2011]. SVR rates of this study 
are awaited. During monotherapy, rapid selection of variants resistant to 
BMS-790052 occurred [Nettles et al., 2011]. The most common resistance 
mutations in HCV genotype 1a patients were observed at residues M28, 
Q30, L31, and Y93 of NS5A. In HCV genotype 1b patients, resistance 
mutations were observed less frequently, predominantly at positions L31 
and Y93 (table 7). These resistance mutations increased the EC50 to BMS-
790052 moderately to strongly [Fridell et al., 2011]. However, no 
crossresistance between BMS-790052 and other DAA agents has been 
reported. 
Collectively, BMS-790052 is a highly promising agent for both 
triple therapy as well as all-DAA combination therapy approaches. 
Other NS5A inhibitors (e.g., BMS-824393, PPI-461, GS-5885) are 
in early clinical development. 
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Table 7.  HCV drug resistance pathways associated to DAAs resistance 
 
Pathway * Resistance Level Amino Acid Substitutions 
NS3 PI Class Specific High A156S/T/V; R155K/Q 
NS3 PI Macrocyclic High D168A/V; R155K+D168V/A 
NS3 PI Linear Ketoamide 
Low V36M; T54A; V36M+T54A 
High A156T+V36M; R155K+V36M; V170A 
NS5A Imino-
thiazolidinone 
Low 
M28; Q30H/R; Q54L; A92V; R157W; 
Y93C+Q30H 
High L31V/M; L31V/M+P58L; Y93C 
NS5B NA High S282T/R 
NS5B NNA 
Moderate H96Q/R; C315Y/F/S; N411S 
High S365A/T/L; M414I/L/T/V 
* PI = protease inhibitor; NA = nucleos(t)ide analogue inhibitor; NNA = non-
nucleos(t)ide analogue inhibitor 
 
 
4.8.3 Management of HCV chronic infection: Standard of Care and 
Direct Acting Anti-viral 
The goal of therapy is to eradicate HCV infection in order to prevent 
the complications of HCV-related liver disease, including 
necroinflammation, fibrosis, cirrhosis, HCC, and death. The endpoint of 
therapy is sustained viral response (SVR), intermediate endpoints are used 
during Standard of Care (SOC) treatment to assess the likelihood of an SVR 
and tailor treatment duration. They include HCV RNA level measurements 
at 4, 12, and 24 weeks of therapy, which are interpreted in comparison to the 
baseline HCV RNA level. When HCV is eradicated, necroinflammation 
ceases and fibrosis progression is halted in non-cirrhotic patients. 
As already mentioned the SOC treatment has different efficacy 
levels among the different HCV genotypes. For this reason guidelines 
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recommend 48 weeks of SOC administration in patients infected with HCV 
genotype 1 and 4 or 24 weeks in case of infection with genotypes 2, 3, 5, 6. 
Several predictors, other than HCV genotypes, for SVR after therapy have 
been identified in the past. Some of them are viral factors like baseline HCV 
RNA levels, some other are related to the host characteristic like body mass 
index, age, insulin resistance, gender, or related to the liver disease, 
including levels of ALT, GGT, the stage of fibrosis or co-infection with 
another hepatotropic virus or with HIV. However, one of the strongest 
predictors in case of HCV genotype 1 infection, have been only recently 
identified as a genetic polymorphisms located in chromosome 19, close to 
the region coding for IL28B (or IFN k3). In a study involving HCV 
genotype 1 infected patients, Ge et al., reported a twofold greater rate of 
SVR for the allele rs12979860 CC genotype in comparison with the TT 
genotype. Such a strong association was not found in HCV genotypes other 
than 1. 
Boceprevir (BOC) and Telaprevir (TVR) are the Direct Acting Anti-
viral to date available for HCV chronic infection. Results from previous 
studies have shown rapid selection and emergence of resistance mutations 
during boceprevir or Telaprevir monotherapy [Susser et al., 2009; Hiraga N 
et al., 2011]. For this reason triple therapy combination including DAA plus 
SOC was tested in clinical trials showing an increment of 24% and 33% in 
the response rates of HCV genotype 1 infected patients to BOC + SOC 
(4wks lead in of SOC + 48wks of combination) and TVR (12wks) + SOC 
(48wks) treatments respectively, comparing to the use of SOC alone [Manns 
et al., 2001; Nelson DR 2010].  
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Therefore, telaprevir- and boceprevir-based triple therapy can be 
considered the novel standard of care for HCV genotype 1 patients. 
 
4.8.4 Treatment failure 
The loss of therapy efficacy or the lack of a response ab initio are 
events known as treatment failure. During HCV chronic infection treatment 
various patterns of HCV treatment failure have been reported, including 
viral nonresponse, viral breakthrough on treatment, and viral relapse after 
treatment completion.  
Non-responders are patients who failed to achieve a decline of 2 log 
HCV RNA IU/ml after 12 weeks of treatment or who never achieved 
undetectable HCV RNA during treatment of a minimum duration of 24 
weeks. 
Relapsers are defined as patients who achieved an end-of-treatment 
response (undetectable HCV RNA at the end of treatment) but subsequently 
relapsed and did not achieve an SVR. The relapse rate after treatment with 
pegylated IFN-a and ribavirin is on the order of 15–25%, but varies 
according to when HCV RNA becomes undetectable during therapy. 
To date patients SOC failure experienced can have the possibility to 
reach an SVR with the new DAAs in a triple therapy. Despite the 
encouraging results of telaprevir- and boceprevir-based triple therapy, 
several cases of drug resistance were observed during treatment, and they 
were confirmed by in vitro phenotype testing. In particular, the prevalence 
of resistance among HCV genotype 1 infected patients after combination 
therapy SOC + BOC (44wks) was 14% and 15% for treatment-naïve and 
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SOC pretreated patients respectively [Poordad et al., 2011; Bacon et al., 
2011].  
Resistant mutation a part, the total failure rates in treatment-na¨ıve 
patients are 20%–30% on triple therapy. In previously treated patients, the 
failure rates range as high as 50% – 60%. Development of persistence of 
viral resistance depends in part on several host and treatment-related 
variables. Failure rates are higher in patients with less favorable genetic 
background (IL- 28 phenotypes CT or TT), including the African-American 
population, prior treatment nonresponders, HIV- or HBVcoinfected patients, 
post-liver-transplant patients, noncompliant patients, and patients with 
advanced fibrosis/cirrhosis. 
Telaprevir is taken, with PEG-IFN-α and ribavirin, at a dose of 750 
mg every eight hours for the first 12 weeks of the treatment. If HCV RNA is 
equal to or greater than 1000 IU/mL at weeks 4 or 12, virologic failure has 
occurred and triple therapy should be discontinued immediately. If the virus 
is detected to any degree at week 24, dual therapy should also be 
discontinued at that point, as the likelihood of achieving SVR is very low. 
When using boceprevir, the treatment algorithm is different and involves a 
4-week period of PEG-INF-α and ribavirin dual therapy, also known as the 
“lead in” period, followed by triple therapy with addition of 800 mg of 
boceprevir every eight hours for a variable period of time; PEG-IFN- α and 
ribavirin will continue until treatment completion. A viral load equal to or 
greater than 100 IU/mL at week 12 is equivalent to virologic failure, and all 
three drugs should be stopped to avoid resistance. Alternatively, any 
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detectable viral load at week 24 again implies again lack of response, and 
treatment should be terminated. 
Failing triple therapy raises concerns regarding possible adverse 
consequences for the liver disease and for this reason these patients must 
continue to be clinically monitored. To evaluate is also the role of resistant 
quasispecies selected and emerged during the treatment for the influence on 
the response to future DAA-based therapy. 
 
5 Bioinformatics: definitions and application to virology 
Bioinformatics is the application of computer science, statistics and 
information theory to the field of biology and medicine, and has become 
indispensible for virology research in recent years. Numerous 
bioinformatics tools are available for general analyses of viral genomes such 
as multiple nucleotide/amino acid sequence alignment, motif identification, 
recombination, genome annotation, and phylogenetic relationships.  Most of 
these tools are available as freeware, and many can be found at the National 
Center for Biotechnology Information (NCBI) at 
http://www.ncbi.nlm.nih.gov or the European Molecular Biology 
Laboratory (EMBL) at http://www.embl.org websites [Yan Q, 2008]. 
The complex genome structure and arrangement of some viruses 
such as overlapping open reading frames (ORF) and translational 
frameshifts, is often challenging for general bioinformatics tools; thus 
software packages specifically designed or optimized for virology research 
have been developed in recent years. Moreover, dedicated public databases 
that function as data repository for treatment history, viral and clinical data 
128 
 
have been established for specific viruses such as influenza virus (Influenza 
Virus Resource at http://www.ncbi.nih.gov/genomes/FLU/FLU.html), 
human immunodeficiency virus (The HIV databases at 
http://www.hiv.lanl.gov/content/index) and coronavirus (SARS 
Bioinformatics Suite 
http://athena.bioc.uvic.ca/database.php?db=Coronaviridae). 
 
5.1 Bioinformatics methods and public databases for HCV 
The natural histories for chronic HCV infections have been well 
characterised, yet the mechanism of pathogenicity of this virus remain 
largely unknown; these include the receptors responsible for viral entry into 
hepatocytes, the viral and host genetic factors required to establish chronic 
infections, and the viral and host genetic factors required for progression to 
HCC. Recent advances made in sequence genomics of a large number of 
organisms will enable further studies and aid in understanding the structure-
function correlation between the virus and its respective host providing a 
unique insight into the process of deciphering the pathogenic mechanisms of 
HCV. 
Within the last ten years, several bioinformatics tools dedicated to 
HCV research have become available. They are mainly nucleotide/amino 
acid sequence analysis tools that can be accessed in public databases 
established for hepatitis viruses (table 8).  
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Table 8:  HCV Databases described in this thesis 
 
Database Internet Address Reference 
Hepatitis C   
Los Alamos HCV Sequence 
Database 
http://hcv.lanl.gov/content/index 
[Kuiken C et 
al., 2005] 
European HCV Database 
(euHCVdb) 
http://euhcvdb.ibcp.fr/edHCVdb/ 
[Combet C et 
al., 2007] 
Japan Hepatitis Virus 
Database 
http://s2as02.genes.nig.ac.jp 
[Shin IT et al., 
2008] 
SeqHepC (under development)  
 
 
Databases dedicated for HCV were initially developed up for 
research and epidemiological purposes. Excluding the alternate reading 
frame protein (ARFP/F), whose function remains unknown, the genome 
structure of HCV is simpler than HBV. The HCV is a positive-sense, single-
stranded RNA virus with a genome that is approximately 9.6kb in size and 
encodes for a unique polyprotein with no overlapping regions. Whilst this 
structure may make it easier to identify clinically important mutations and to 
study their effects compared to the HBV genome, there is less constraint for 
mutations to occur and the rate of mutation is substantially higher (0.9x10-3 
base substitutions/site/year). This is the primary cause of the high genetic 
heterogeneity observed in HCV, accounting for at least 6 HCV genotypes 
and 18 subtypes with genomes that differ by 24-30% and 15-23% 
respectively [Simmonds P et al., 2005]. 
The main public databases established for HCV research and 
epidemiological studies include the Los Alamos HCV Sequence Database 
(http://hcv.lanl.gov/content/index) [Kuiken C, 2010], the European HCV 
Database (http://euhcvdb.ibcp.fr/euHCVdb/ - euHCVdb) [Combet C et al., 
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2007] and the Japan Hepatitis Virus Database (http://s2as02.genes.nig.ac.jp) 
[Shin IT et al., 2007]. Both Los Alamos HCV Sequence Database and 
euHCVdb contain >1,000 HCV genome sequences, and have dedicated 
tools that enable sequence retrieval using selection criteria such as HCV full 
genome/specific region, genotype/subtype, and treatment history. In recent 
years, new HCV treatment databases and dedicated tools have been 
developed in provision for studying and analyzing the effects of new anti-
HCV drugs, the directly acting antiviral (DAAs). 
The high genetic heterogeneity of HCV will affect the future use of 
DAAs, and drug resistance associated mutations are expected to emerge and 
progress to complex profiles as more DAAs are approved for the 
management of chronic HCV infections. In vitro drug susceptibility 
phenotype studies have already showed different patterns of amino acid 
substitutions can confer different levels of drug resistance. A summary of 
amino acid substitutions that are currently known to confer resistance to the 
main classes of DAA is shown in Table 7. 
 
5.2 Aim of the study 
In 2010, a joint collaboration was established between the Victorian 
Infectious Diseases Reference Laboratory (VIDRL) of Melbourne Health, 
Australia and the Hepatitis C Virus Research Laboratory of the Institute of 
Medical and Veterinary Science (IMVS), Australia to develop a web 
assessable sequence analysis tool (SeqHepC) for the management of 
patients with resistance to the DAAs for chronic hepatitis C.  
My personal aims inside this main project were to: 
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- List all major HCV genotypes (references if possible) 
- List as many HCV subtypes as possible (references if possible) 
- Calculate proportion of sequence divergence between all HCV 
subtypes (pairwise analyses) 
- Focus on HCV NS3 protease and NS5B polymerase to start off with 
how useful would these genes be for subtyping and If useful, what is 
the minimum region for subtyping 
- Collect representative full length HCV sequences as references for 
SeqHepC 
- Determine all before any DAA drugs became available. 
 
5.3 Materials and Methods 
A total of 1,387 full-length HCV sequences downloaded from 
GenBank (www.ncbi.nlm.nih.gov/genbank/) were analysed for genotyping, 
subtyping and divergence analysis. Los Alamos HCV database tools were 
used to select and align sequences. Alignments in particular, have been 
carried out with a new implementing method that use probabilistic models 
called profile hidden Markov models (profile HMMs, 
http://hmmer.janelia.org/). Compared to the Basic Local Alignment Search 
Tool (BLAST), HMMs is more accurate and more able to detect remote 
homologs because of the strength of its underlying mathematical models.  
Sequence editing and manual correction were performed with 
Bioedit (www.mbio.ncsu.edu/bioedit/bioedit.html) while MEGA 4.0 
program (www.megasoftware.net/mega4/mega.html) was used for 
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phylogenetic analysis. Particularly bootstrap consensus trees were obtained 
with the Neighbor-Joining method (1000 replicates). 
 
5.4 Results 
Development of SeqHepC began with a comprehensive evaluation of 
all available full-length HCV genome sequences from the GenBank 
database. A total of 1,387 full-length HCV sequences were downloaded 
from GenBank. Phylogenetic analysis showed that 248 sequences were 
duplicate submissions (identical sequences with different submission 
number), and thus were removed from subsequent analysis (figure 18). 
The HCV genotype and subtype of the remaining 1,139 unique 
sequences were as follow: 933 HCV genotype 1 (1a = 550, 1b = 380, and 1c 
= 3) and 206 non-1 HCV genotypes. Based on the HCV genotype 
nomenclature system proposed by Simmonds et al [Simmonds et al., 2005], 
the genotype, subtype and drug-naïve status could be confirmed for 228 of 
the HCV full length genome sequences analysed using the data available in 
the Los Alamos HCV Sequence Database and the euHCVdb database 
(Figure 18-19). Of these, 185 sequences were HCV genotype 1 (126 = 1a; 
59 = 1b) and 43 were non-1 HCV genotypes.  
Thirty-two sequences representing all the genotypes and most of the 
subtypes were then selected from different intragenotype clades as the 
reference set to use for genotyping and drug resistance analysis in SeqHepC 
(Figure 18, 20). The percentages of divergence between these 32 HCV 
sequences are shown as a matrix in Figure 21. 
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As the amino acid substitutions, known to be associated with PI resistance, 
are located within the first one third of the NS3 gene, a region where the 
catalytic site of the enzyme is encoded, we identified and tested a minimal 
region of first 543 nucleotides including PI resistant mutation. Phylogenetic 
analysis and pairwise comparisons performed on this minimal NS3 region 
showed it is sufficient to determine HCV genotypes/subtypes (Figures 22 - 
23) [data submitted to Antiviral Therapy]. 
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Figure 19. An unrooted neighbor-joining tree of 228 full-length HCV 
genome sequences determined from drug-naïve individuals, using the 
Maximum Composite Likelihood substitution model.  The tree is a 
consensus of 1,000 datasets generated using the bootstrap re-sampling 
method.  Similar results were obtained from unrooted trees of the HCV 
regions coding for the DAAs targets (NS3, NS5A, NS5B). 
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                          A                                                          B 
 
Figure 20.  The 32 HCV full-length sequences from GenBank used as 
reference sequences in SeqHepC.  (A) List of the 32 HBV sequences 
showing the corresponding GenBank accession number, HCV genotype and 
subtype in parenthesis, and length of sequence.  (B) A consensus neighbor-
joining tree of 1,000 datasets (by the bootstrap re-sampling method) 
generated using Maximum Composite Likelihood substitution model. The 
tree shows the clustering profiles of the 32 reference HCV full-length 
sequences. 
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Figure 22. An unrooted neighbor-joining tree of 228 HCV sequences. The 
genomic region analysed was the NS3 minimal region (543nt) that 
correspond to the protease domain where the PI resistance mutations would 
be found. The tree is a consensus of 1,000 datasets generated using the 
bootstrap re-sampling method and analysed with Maximum Composite 
Likelihood substitution model. 
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Figure 23. Analysis on the set of 32 reference sequences for SeqHepC 
system. Between Genotype analysis in the NS3 complete region (upper 
matrix) and in the NS3 minimal region (lower matrix). Strains belonging to 
a same genotype have been grouped using the Taxa and Group definition 
option in Mega 4.0; the phylogenetic distances are expressed as means of 
nucleotide differences between groups (below the diagonal, computed in 
Mega 4.0) or as percentage divergence calculated on 1866 and 543 valid 
sites for the analysis in NS3 complete region and NS3 minimal region 
respectively [Submitted to Antiviral Therapy]. 
 
 
5.5  Discussion 
Bioinformatics for hepatitis viruses started some years ago with 
mainly general tools and few dedicated allowing purely research analysis. 
Until 2 years ago three main web acess databases were available for HCV 
allowing phylogenetic analysis including sequence alignment, genotyping, 
subtyping.     
 
Num of nt. differences on a total of 543 sites 
D
iverge
n
ce (%
) 
Complete NS3 region  
Genotype 1 2 3 4 5 6 7 
1 29.26 29.90 26.21 27.22 27.71 30.98 
2 546 31.51 29.42 29.42 30.33 30.98 
3 558 588 30.17 29.47 30.55 31.14 
4 489 549 563 27.38 28.19 31.30 
5 508 549 550 511 28.35 31.89 
6 517 566 570 526 529 31.67 
7 578 578 581 584 595 591 
NS3  minimal region (543nt) 
Genotype 1 2 3 4 5 6 7 
1 34.27 33.90 30.71 30.52 29.78 36.70 
2 183 36.52 34.08 34.83 34.46 36.52 
3 181 195 34.46 33.71 32.58 35.21 
4 164 182 184 33.33 32.02 37.08 
5 163 186 180 178 29.03 37.83 
6 159 184 174 171 155 36.89 
7 196 195 188 198 202 197 
Num of nt. differences on a total of 1866 sites 
D
iverge
n
ce (%
) 
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That was considered enough since the only viral predicting factor for 
HCV  treatment outcome was the genotype.  
The arising DAAs era in the HCV treatment is now the driving force 
for the development of new databases and bioinformatic tools HCV 
dedicated including not only analisys for genotype/subtype prediction but 
also resistance variants identification. 
Despite the new interest in creating HCV web access databases, few 
of them are actually including the necessary informations and tools for a 
correct identification of resistance. None of the available Databases is 
intended to be a real updated diagnosis instrument helping the clinician in 
taking therapy decision. 
In 2010, a joint collaboration was established between the Victorian 
Infectious Diseases Reference Laboratory (VIDRL) of Melbourne Health, 
Australia and the Hepatitis C Virus Research Laboratory of the Institute of 
Medical and Veterinary Science (IMVS), Australia to develop a web 
assessable sequence analysis tool (SeqHepC) for the management of 
patients with resistance to the DAAs for chronic hepatitis C.  
The project needed at first to collect a limited and manageable 
number of full length reference sequences from all the major HCV 
genotypes and subtypes.  
We used the HCV Los Alamos Database and the tools included for 
query selection of a large number of full length HCV sequences. A total of 
228 sequences were selected by unique submition, confirmed 
genotypes/subtypes by Simmonds consensus proposal and by naïve status. 
141 
 
An unrooted tree was generated to confirm genotype/subtype of the 228 
sequences and among them, 32 strains were chosen from the main branches 
of the tree.  
The big skimming prompet us to proceed to the next phase of our 
project: to focus on HCV NS3 protease and NS5B polymerase to start off 
with how useful would these genes be for subtyping and If useful, what is 
the minimum region for subtyping. 
The NS3 and NS5B regions were both found to be useful for 
genotyping and subtyping. We succeeded in identifying a minimal region of 
543 nucleotides located in the NS3 sequence including all the identified 
protease inhibitor resistant mutations. Such a minimal region was also 
useful for genotyping and even subtyping as showed by the phylogenetic 
tree and divergence data (table 23).     
A working version of SeqHepC is currently undergoing alpha 
testing. The program is designed to enable genotyping and mutational 
analysis of HCV sequences, which can be submitted either as a nucleotide 
sequence or deduced amino acid sequence. The input sequence would be 
compared to the 32 full length HCV reference sequences to determine the 
genotype, followed by comparison with the reference sequence of an 
equivalent genotype for the assessment of drug-resistance associated amino 
acid substitutions.  Reports generated are date and time stamped, and will 
display data including the HCV genome region covered by the submitted 
sequence, a list of clinically significant amino acid substitutions, and 
predicted PI susceptibility. All drug resistance associated amino acid 
substitutions reported are currently based on the peer-reviewed literatures 
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for the HCV NS3 protein. The data generated can be also used to further 
develop HCV drug resistance interpretation algorithms, especially when it 
can be integrated in a local database with the clinical data (therapeutic 
histories, HCV viral load levels, and liver function test results) of patients 
from whom the viral sequences were determined. A future goal is to enable 
the database to be mined using artificial intelligence algorithms to aid in the 
rapid identification of novel HCV drug resistance mutation(s) (Figure 24). 
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6. Conclusion 
Chronic hepatitis viruses are a huge burden affecting health of 
hundreds million people worldwide and new infection number is costantly 
incrementing because of the high infectivity level of these viruses and their 
ability to persist and replicate in the host for many years or lifelong.  
The Hepatitis B and C viruses (HBV, HCV) are causing the great 
majority of the viral chronic hepatitis and if not treated they lead to 
progressive liver diseases including fibrosis, chirrosis and hepatocellular 
carcinoma. 
From the time of their first identification several drugs against HBV 
and HCV have been developed in the attempt to cure or slow down the liver 
disease and possibly to eradicate the infection.  
The high viral heterogeneity is one of the main factors affecting the 
success of the therapy as treatment failure is mostly associated to viral 
resistant variants.  
In this thesis we aimed to give a contribution to the study of the 
hepatitis viruses heterogeneity considering its pivotal role in case of anti-
viral therapy failure.  
We succeeded developing a sensitive and specific assay for the study 
of early dynamics HBV resistant variants and demonstrating their presence, 
as minor population, in naïve patient that later showed a no response therapy 
associated to resistant variants. Further analysis and a larger cohort of 
patient are needed to better understand the role of the HBV resistant variants 
but given the results obtained in this thesis, our assay will be useful in the 
future as both a research instrument for deep and extensive analysis of 
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resistant quasispecies and a predictive test for sustained responders in HBV 
treatment. 
Concerning HCV, our contribution was in an accurate selection and 
analysis of a large number of HCV sequences to reach a limited but well 
represented number of references needed by the SeqHepC program. The 
SeqHepC will be a web access database working as a sequence repository 
but also including tools for extensive and rapid bioinformatic analysis 
comparing an imput sequence to the references collected during our study. 
Clinical informations from patients and in vitro phenotypic data for 
resistance confirmation will be also included and managed by the system as 
an auto-updating learning artificial intelligence. Finally, SeqHepC will be a 
very useful tool for research and helping clinician in the complex 
management of the new therapies available in the next years.  
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